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PART I 
BACKGROUND 

CHAPTER 1 
INTRODUCTION AND OUTLINE OF THE PROJECT 
Jo expect eVeI' to treat the head by it,e!/, apart /rom 
t/'e body a6 a whole, i6 ,,/tel' /otly, 
(Plato, Charmides) 
The rationale to study a potential adverse reaction of a specific drug mainly depends 
on three questions: 1) how serious is the adverse reaction? 2) what is the incidence of 
the adverse reaction among users of the dlUg?, and 3) what is the frequency of 
consumption of the specific dlUg in the population? Especially dlUgs which are 
frequently prescribed and used, also rare serious adverse reactions may be important, 
such as thromboembolism in users of oral contraceptives. 
The present thesis sunmlarizes our studies of a potential serious adverse reaction of 
sumatriptan, which turned out to be relatively frequent among users. This new drug, 
used in the treatment of acute attacks of migraine, appears to have more actions 
outside the head than was initially thought. 
Migraine 
The word migraine is derived from Galen's term hemicrania. Indeed, .the condition is 
characterized by attacks of one-sided headache. The pain pulsates, is aggravated by 
routine physical activity, and associated with nausea and photo- and phonophobia (1). 
By definition, migraine attacks last between 4 and 72 hours. The attacks mayor may 
not be accompanied by preceding symptoms, the aura. 
Migraine has probably always affected mankind. In ancient Egypt, the gods 
themselves had headache (2). In the book on neurology by the Dutch physician Iason 
Pratensis (1486-1558), entitled 'De cerebri morbis', one chapter is about migraine. He 
concluded that the causes of migraine include warmth, too much working, too frequent 
use of hot baths and long physical exercise (3). In the 17tll century, Charles Le Pois 
noted that 'it has to be absolutely stated that sleep is a relative of migraine, and 
migraine itself arises from the same cause, namely an aqueous humour that flows over 
in the head, but is agitated and fermented by some sudden aerial storm and 
perturbation' (2). 
Migraine is a common condition (4), which is often incapacitating, causes a 
substantial loss of working days, and is an important public health problem (5). 
Migraine is more common among females than among males. It has been estimated 
that it affects 4 to 19 percent of adult men and 8 to 29 percent of adult women (4). 
The prevalence tends to decrease slowly with age, beginning in females in their 
forties. It has been noted that over time the severity of headaches does not change in 
males but decreases in women, and headaches, among those who continue to have 
headaches, become more frequent with age in females but not in males (6). 
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Treatment of migraine 
The treatment of migraine can be divided into treatment of acute attacks, and 
prophylactic treatment. Non-drug treatment should be the first choice. For 
prophylaxis, this concerns identificatjon and avoidance of provoking factors. For acute 
attacks, this consists of bed rest in a dark, quite, cool room. 
Drug treatment of acute attacks (7) includes analgesics such as aspirin and 
acetaminophen, other non steroidal antiinflammatory drugs, and serotonin agonists 
such as ergotamine, dihydroergotamine and, since 1991, sumatriptan. Prophylactic 
drug treatment includes (7) serotonin influencing drugs such as methysergide, 
amitriptyline or phenelzine, {3-adrenergic antagonists such as propranolol and 
metoprolol, and calcium-channel blockers such as nifedipine and analgesics. 
Smnatriptan: potential problems 
In May 1991, The Netherlands was the first countly in the world to register 
sumatriptan. Within one year after registration, the Netherlands Centre for Monitoring 
of Adverse Reactions to Drugs received several reports concerning chest pain 
attributed to use of sumatriptan. A few months later, the Centre received a report on a 
middle-aged female, who experienced an acute myocardial infarction shortly after 
subcutaneous administration of sumatriptan. These reports on (potential) serious 
adverse reactions to a new drug made us decide to perform a pharmaco-epidemiologic 
study on the adverse reactions of sumatriptan which is described in this tllesis. 
Outline of the project 
The thesis comprises three parts. In part 1, the general background of the project is 
given. In part 2, the emergence of the potential problem is described as observed by 
the Netherlands Centre for Monitoring of Adverse Reactions to Drugs. In part 3, the 
exploration of the potential problem is described. 
There is no doubt that premarketing randomized clinical trials supply us with a lot 
of information about new drugs. However, these trials also have their limitations, and 
after marketing of a drug continuous post marketing surveillance is necessary (chapter 
2). 
One method for post marketing surveillance makes use of spontaneous reporting 
schemes. In chapter 3, some characteristics of the Netllerlands Centre for Monitoring 
of Adverse Reactions to Drugs are given. One group of adverse reactions concerns 
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drug-induced chest pain and myocardial infarction. Spontaneous reports of drug-
induced chest pain or myocardial infarction to the Dutch Centre between 1975 and 
1995 are described in chapter 4. In particular, many reports concerned sumatriptan-
induced chest pain or myocardial infarction (33 reports). Some of the sumatriptan-
associated cardiovascular adverse reactions are described in more detail in chapter 5. 
Since the association between use of sumatriptan and cardiac events was confirmed by 
case reports in the literature, the question whether there was cause for concern seemed 
to be justified (chapter 6). 
In chapter 7, details on the design and enrolment of a cohort study on sllmatriptan 
related chest pain are given. In particular, the frequency and character of adverse 
reactions to sumatriptan as reported by drug-dispensing general practitioners and 
patients are discussed. In chapter 8, the pattern of use and overuse as reported by the 
patients in the pharmaco-epidemiologic study is described. In chapter 9, determinants 
and characteristics of chest pain to sumatriptan are assessed, whereas in chapter 10 
differences in exercise testing between patients with and without chest pain after use of 
sumatriptan are studied. 
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CHAPTER 2 
POST MARKETING SURVEILLANCE 
2.1 Introduction 
Drugs are being used by more and more people, and drug use has become a factor of 
increasing economical importance in health expenditure. The most consistent finding 
in utilization studies is that use of prescribed drugs increases with age and is higher in 
females (1). Use of drugs has decreased the mortality and morbidity of several 
diseases, as well as improved the quality of life of many patients. In comparison with 
other therapeutic interventions, medications are remarkably effective, cost-effective, 
and safe (2, 3). And although some people are worried about the growing consumption 
of drugs, results from some studies have suggested that several specific drugs are less 
used than may be necessary (4, 5). In this chapter on postmarketing surveillance, 
several aspects of safe and appropriate drug use will be discussed. 
In chapter 2.2 the most important definitions used in post marketing surveillance 
will be given. In chapter 2.3, some details will be given on the premarketing and the 
marketing stages. In chapter 2.4, the history of postmarketing surveillance of adverse 
reactions will be reviewed. In chapter 2.5, several limitations of premarketing studies 
are discussed, whereas in chapter 2.6 methods and systems for postmarketing 
surveillance will be explored. 
2.2 Definitions 
The Dutch Health Council defined postmarketing surveillance as 'the systematic 
surveillance of and research on all intended and unintended effects (beneficial and 
adverse) caused by drugs after marketing' (6). A shorter definition is 'the close 
observation of drug effects following marketing' (7). According to these definitions 
postmarketing surveillance is more than adverse reaction monitoring. This chapter, 
however, will almost entirely focus on unintended effects of drugs after marketing. 
Directive 93/39/EEC of the European Community was published in June 1993, and 
defined pharmacovigilallce as the 'collection of relevant information for the 
surveillance of medicinal products, particularly their undesirable effect on humans, 
and the scientific evaluation of this information. Pharmacovigilance concerns also the 
collection of information on fj'equently observed misuses and serious abuses of 
medicinal products.' 
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Pharmacoepidelllio!ogy can be defined as the study of drugs as determinants of 
health and disease in the general unselected population (8). The term 
'pharmacoepidemiology' first appeared in the medical literature in a British Medical 
Journal editorial in 1984 (9). 
The following definitions are mainly based on those used in the Directives and 
Regulations of the European Union and the definitions of the WHO. An adverse 
reaction means a reaction which is harmful and unintended and which occurs at doses 
normally used in man for the prophylaxis, diagnosis or treatment of disease or the 
modification of physiological function. A serious adverse drug reaction is defined as 
an adverse drug reaction which is fatal, life-tin'eatening, disabling, incapacitating or 
which results in or prolongs hospitalisation. An unexpected adverse reaction is an 
adverse reaction which is not mentioned in the summary of product characteristics. 
Adverse reactions to drugs can be classified into type A and type B reactions (10). 
Type A adverse reactions are the result of the pharmacological activity of a drug, and 
are largely predictable and usually dose-dependent. Examples of type A reactions 
include bradycardia by beta-blockers and hypoglycaemia by antidiabetics. Type B 
reactions are not dependent on the pharmacological activity of a drug, and are 
unpredictable and not dose-dependent. An example of a type B reaction is an 
immunoallergic reaction. Drug interactions may result from changes in either the 
pharmacokinetics or the pharmacodynamics of the drugs involved (11). 
Pharmacokinetic interactions may take place at any stage of absorption, distribution, 
metabolism or excretion. 
Sometimes, components which are added to active drug substances may cause 
adverse reactions, such as in the disaster in 1937 with the elixir of sulphanilamide, 
which contained diethylene glycol. OUler examples are lactose induced diarrhoea (12) 
and bioavailability problems with digoxin due to a change in particle size (13). 
Three different stages in the life of a drug can be distinguished: the mmarketing 
stage, the marketing stage, and the postmarketing stage. Marketing means the process 
in which a new drug is put onto the market after registration by the auUlOrities, 
separating the premarketing ('test') stage and the postmarketing stage. 
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2.3 The premar\<eting & marketing stage 
a. Drug development: The premarketing stage 
Substances may become dl1lgs in different ways: from primitive medicine or folklore 
(e.g. quinine for malaria), from investigation of natural products (e.g. digitalis), from 
synthesis of new chemicals resembling natural substances (e.g. aspirin) or existing 
dl1lgs, or from studies of physiological and pathological processes in animals and 
humans (e.g. insulin). In present times, whatever the background or reason for belief 
in the action of a compound, before a new potential dlUg can be used for the treatment 
of patients, it should be tested, in-vitro and in-vivo, and in animals and in humans. 
Before the 20th century, only anecdotal examples of trials on the effects of dlUgs 
are available. One of the first recorded, if not the first, therapeutic trial was 
performed in the early 17th century: In 1600, four ships were sent to India by the East 
India Company, of which ships one was provided with lemon juice as part of the 
rations; this crew was free from scurvy. Nowadays most new drugs are discovered 
and developed by the pharmaceutical industlY, and before marketing of a dl1lg tlu'ee 
phases of studying dl1lgs in humans can be distinguished: 
Phase I - The dlUg is tested on a small group of human volunteers (N =20-80) in 
order to obtain data on pharmacokinetic and pharmacodynamic 
characteristics of the drug. In approximately 30% of compounds, 
unacceptable risks are present and further testing is terminated. 
Phase II - In this phase the dl1lg is tested on small groups of patients (N S; 200). 
Among others, the optimal dose is assessed, and the first estimates of 
potential therapeutic efficacy can be obtained. 
Phase III - In tllis phase large experimental studies, trials, are performed. Most 
trials are nowadays randomised, placebo controlled, and (double) 
blinded. 
Before phase I, many chemical substances are syntllesized. It has been estimated that 
2300, 4300 and 6200 compounds are synthesized for each new drug that is approved 
for Japanese, European, and United States companies, respectively (14). The studies 
performed in phase III are the most important for registration and for clinical practice. 
The "double blind, randomized parallel group trial", can be seen as the paradigm to 
demonstrate the efficacy of a new dlug. 
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The majority of controlled clinical trials of drugs are carried Ollt in the pre-
marketing phase of new drug development, although there are exceptions (15). Control 
groups may include placebo-treated patients, patients treated using registered standard 
drugs or both. The main advantages of these studies are those of randomization, 
placebo control and blinding in the measurement of the outcomes, to achieve 
comparability of prognosis, extraneous effects and observation (16). In chapter 2.5, 
some limitations and disadvantages of clinical trials will be discussed. 
b. Registration: The marketing stage 
The marketing stage of a drug is for a great part a matter of regulatory authorities. In 
January 1995, the European Medicines Evaluation Agency (EMEA) was established, 
and since then a new system has started of marketing medicines in countries of the 
European Community. The EMEA, which is based in London, acts as a coordinating 
centre, housing and servicing the Conmlittee for Proprietary Medicinal Products 
(CPMP), to advise the European licensing authority (European Conmlission). From 
1998 there will be two routes to a European licence. One through the Celllralized 
Procedure and the other tlu'ough the Decentralized Procedure. In the Decentralized 
procedure, again there are two routes. A manufacturer may apply for registration in 
one country or make applications simultaneously in all Member States. Once one 
Member State has granted the licence the assessment procedure will be halted in all 
other Member States, which must then either recognise the authorization or raise 
objections. 
In the U.S. tile secretary of Health and Human Services has the authority, to 
regulate approval of drugs offered in interstate commerce, delegated to the Food and 
Drug Administration (FDA). The regulatory process begins when a company submits 
a so called 'Investigational New Drug Application' (IND) , which describes the 
'chemical composition of the drug, the results of preclinical investigations, including 
animal studies, and a protocol for clinical investigations. This application is reviewed 
by the FDA, and if there is no objection, phase I - III studies can start. Of these drugs 
under investigation, the FDA asks for reports annually and immediately of reactions 
that are serious (,,; 10 days) or life tllfeatening ("; 3 days). If the human 
investigations are successful, the company submits a so called 'New Drug Application' 
(NDA) to the FDA. After review and approval of the NDA by the FDA, marketing of 
the drug is allowed. 
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In 1993, the Dutch Medicines Evaluation Board (DMEB) handled 397 products, 
compared to 413 in 1992 (17). The 397 products concerned 195 national marketing 
authorizations (193 in 1992), 134 through the EU system (1992, 111) and 68 
variations to national product licences (1992, 109). A total of 957 registration 
applications were received by the DMEB in 1993, of which 460 were for parallel 
imports and identical products (in 1992 814 and 269 respectively). 604 products were 
approved, of which 384 were parallel imports (578 and 275 respectively in 1992). 16 
of the approvals were for new chemical entities. 
The number of pharmaceuticals registered in the Netherlands at the begilming of 
January 1994 was 8,498 of which 2,332 were parallel imports. This compares with 
8,175 and 2,080 in January 1993. 
2.4 History of 'postmarketing' monitoring of adverse drug reactions 
Even in the ancient world it was known that medicine not only cures patients, but can 
also be bad for patients. The need for prescribers to be cautious was reflected already 
in the statement in the Babylonian 'Code of Hammurabi' (2200 B.C.) that "a physician 
who caused a patient's death should lose his hand" (18). 
One of the oldest descriptions of an adverse reaction to a specific drng concerns 
William Withe rings description of the side effects of digitalis in 1785 (19). In the 19th 
century, there was in the UK concern about the safety of chloroform anaesthesia (20), 
although the second Hyderabad Chloroform Commission still claimed that 'chloroform 
is as safe as whisky and water' (21). However, as with pharmacotherapy in general, 
most advancements in knowledge about postmarketing adverse reactions to drngs, have 
occurred after 1900. In 1906, the Pure Food and Drngs Act was passed in the USA 
which was primarily focused on impure and contaminated food and drugs. During the 
rest of the 20tll century drng safety has attracted particular attention in cases of 
disasters associated with certain drugs. 
At the end of the first World War there was an official enquiry of the Medical 
Research Council in the UK concerning an outbreak of massive hepatic necrosis in 
patients treated for syphilis with neoarsphenamine benzoate at the Cherry Hinton 
Military Hospital near Cambridge in 1917 and 1918. The Committee reported tllat the 
most probable cause of the outbreak was tlle toxicity of the organo-arsenical 
compounds (22), although other authors claimed that an infection was the cause (23). 
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In retrospect it is likely that it concerned viral hepatitis. In 1923 a physician in 
London described jaundice in a patient who had been treated for gout with cinchophen 
(24). 
In January 1937, after careful animal and clinical studies, Long and Bliss endorsed 
the use of sUlphanilamide for streptococcal infections (25). Among other companies 
(sulphanilamide was not subject to patent restrictions), the S.B. Massengill Company 
of Bristol, Termessee began to produce sUlphanilamide. This company decided to 
produce also a liquid preparation of sulphanilamide, consisting of 10% sulphanilamide, 
72% diethylene glycol, 16% water, and small amounts of elixir flavour, raspberry 
extract, saccharin solution, amaranth, and caramel (26). Despite the lack of ethanol, 
the solvent was called "Elixir Sulphanilamide". By early September 1937,240 gallons 
of Elixir Sulphanilamide had been produced by the Massengill Company. However, 
before the end of October 1937, both the American Medical Association, the Food and 
Dl1lg Administration (FDA) and the Massengill Company were aware of several 
patients who had unexpectedly died from renal failure after ingesting Elixir 
Sulphanilamide. Because nephrotoxicity was not a known adverse reaction of 
sulphanilamide, the diluent diethylene glycol was very soon suspected to have caused 
this adverse reaction. The legal grounds for action on the part of the FDA were 
limited because of the absence of appropriate regulatory law. Fortunately, because 
Elixir Sulphanilamide was marketed as an 'elixir' but lacked ethanol, the FDA could 
seize the dl1lg for 'misbranding regulation', and retrieved 228 of the 240 gallons 
before distribution to patients. It is estimated that if all 240 gallons had been 
consumed, the number of deaths could amount to 4000 (27). Still, in its short 
marketing period the Elixir had caused at least 76 deaths due to its 72 % content of 
diethylene glycol (28). Diethylene glycol is still manufactured as an industrial solvent, 
for example in anti-freeze solutions. It received some attention a few years ago 
because several white wines in Europe were found to be contaminated by diethylene 
glycol that had been added by wine producers to improve the taste of the wine (29). 
Furthermore, paracetamol elixirs with diethylene glycol (which was possibly 
substituted for the more expensive propylene glycol) were associated with epidemics 
of fatal renal failure in children in Nigeria (30) and Bangladesh between 1990 and 
1992 (31). 
Partly because of the 'Elixir epidemic' in 1937 and the attention it attracted, the 
Federal Food, Drug and Cosmetic Act was passed by the U.S. Congress and signed 
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into law by President Franklin Delano Roosevelt in 1938. This legislation required 
that toxicity must be tested before the release of a new drug or preparation. Now, for 
the first time, pharmaceutical manufacturers had to show product safety before 
distribution. Furthermore, formula disclosures of all active ingredients had to be 
given. However, no proof of efficacy was required. 
In 1951, the Humphry-Dunham Drug Prescription Act in the US separated drugs 
into those requiring a physician's prescription and those that could be sold over the 
counter (32). One of the first textbooks of adverse reactions was published in 1952 
(33). 
In 1950 the first fatal case of aplastic anaemia due to chloramphenicol was 
described (34). As a result a systematic attempt to record adverse reactions to drugs 
started in the US in 1955, when a registry for blood dyscrasias under the auspices of 
the American Medical Association was set up. The idea came from two 
haematologists, Wintrobe and Sturgeon, who had both observed aplastic anaemia in 
patients treated with chloramphenicol (35). However, this system stopped, due to lack 
of cooperation from physicians. 
Thalidomide was introduced in 1956 in West Germany and in 1958 in the UK as a 
hypnotic with few residual side effects. However, in 1961, use of thalidomide was 
associated with a specific form of congenital abnormality, phocomelia (36, 37). Case 
reports of phocomelia in exposed patients were followed by case-control studies (38), 
analyses of secular trends (39) and a retrospective cohort study (40). An estimated 
10,000 children worldwide were born with this birth defect. Fortnnately, the drug had 
not yet been marketed in the U.S. primarily because of the foot-dragging of a FDA 
reviewer, Dr. Francis Kelsey. 
In 1962, six months after the thalidomide disaster became known, the Fitteenth 
World Health Assembly recognized the seriousness of drug safety problems and 
recommended first measures for dealing with them, finally resulting in Resolution 
WHA20.51 of May 1967 in which the basis was laid for an international system for 
monitoring of adverse reactions to drugs. The WHO started with a pilot project on the 
feasibility of an international system for monitoring of adverse reactions to drugs, with 
data provided by 10 countries (Australia, Canada, Czechoslovakia, Federal Republic 
of Germany, Ireland, The Netherlands, New Zealand, Sweden, the United Kingdom, 
and the USA, later joined by Denmark and Norway). The 23rd World Health 
Assembly initiated the operational phase of the international drug monitoring project. 
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In the US, in 1963 the Kefauver-Harris Amendments came into law, strengthening 
the requirements for testing of drug safety and efficacy prior to marketing of a drug. 
Since the thalidomide disaster there have been problems with several drugs, and 
some drugs have even been withdrawn from the market (41). Examples of important 
adverse reactions to drugs are Reye's syndrome by aspirin in children (42), 
diethylstilbestrol (DES) and adenocarcinoma of the vagina (43), practolol and 
sclerosing peritonitis (44), and adverse reactions to triazolam (45). More recently 
examples consist of the analgesic glafenine (46) and the antibiotic Centoxin which 
were withdrawn from the market, and the restriction of the indication for ibopamine 
(47). 
2.5 Limitations of premarketing studies 
As was mentioned in paragraph 2.2, the randomized trial provides a powerful means 
to demonstrate the efficacy and the most frequent adverse reactions of a drug. 
However, trials, which are mainly performed before marketing, have several 
limitations, some of which are summarized in table 1. 
TABLE 1 
Potential limitations of clinical trials 
Inherelll limitations 
1. Selection of patients (generalizability) 
2. Limitations to sample size 
3. Limitations to follow-up period 
4. Expensive 
Other limitations 
4. Randomisation not always successful 
5. Often only secondary or intermediate end points 
6. Not all specific tests can be done 
7. Often comparison with placebo, rather than It next best" 
8. Blinding sometimes difficult or not possible 
These limitations can be classified into those that are inherent to the setting of the 
premarketing trials, and others. A few limitations will be briefly discussed. 
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Limitations inherent to the setting 
Generalizability Patients who enrol in premarketing clinical trials differ from patients 
who receive the dmg after marketing. Important groups of patients who are less often 
studied in the clinical trials include the elderly, children, females and patients with 
concomitant diseases or drug use. Examples of differences between the sick 
population, the therapist's target population of patients, and the study population are 
given by Collet, Boissel, and the VALIDATA Group (48). In the GISSI study, on the 
effect of thrombolytic treatment in acute myocardial infarction, of the 31,826 patients 
admitted with an acute myocardial infarction, 11,806 patients (37%) were included in 
the study (49). In the international randomized trial on the effect of surgery for carotid 
stenosis, more than two times the study popUlation was excluded from the study, and 
had innnediate surgical treatment (50). The latter example shows that in clinical trials 
the inclusion of patients is not only based on the criteria in the protocol, but also 
secondary to consideration of optimal patient treatment. Hence, generalizability is not 
always straightforward. 
Limited sample sizes A priori sample size calculations of clinical trials are almost 
invariably based on the potential to show a beneficial effect of the drug(s) of 
investigation. Before marketing, in trials, between 500 and 3,000 subjects are usually 
exposed to a drug. In general this means that there is a chance of 95 % of observing at 
least one adverse reaction with a frequency of 1 per 160 and 1 per 1,000 exposed 
subjects respectively. Such frequency is still high for many adverse reactions. 
Other limitations 
Use of placebos In the nineteenth century a placebo effect was defined as 'quality 
ascribed to any drug prescribed to please the patient rather than to be useful'. More 
recently, G0tzsche defined a placebo as follows (51): 'A placebo is an intervention 
which is believed to lack a specific effect-i.e., an effect for which an empirically 
supported theory exists for its mechanism of action-on the condition in question, but 
which has been demonstrated to be better than no intervention.' Although a placebo is 
a substance without known pharmacological effects, both patients and healthy 
volunteers attribute effects to it (52). In a review of 109 double-blind, placebo 
controlled studies involving 1228 healthy volunteers, it was shown that adverse events 
were reported by 19% of the volunteers after use of a placebo (53). 
The majority of randomized clinical trials use placebo groups as comparison (54). 
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Besides the question whether it is ethical to give patients placebo treatment and 
withhold the 'best proven' or 'next best' treatment, as Bradford Hill already pointed 
out (55), these controlled trials are in fact of limited value for clinical practice when 
the treatment tested has available alternatives. Most important is not whether the new 
treatment is better than nothing (or than a placebo), but whether the efficacy and 
safety of the new treatment is similar or better than an already existing treatment. 
Fortunately, there are more and more authors who promote the comparison of new 
drugs against active treatment (if available), rather than against placebos (56). Some 
have even suggested additional post marketing randomised trials (57). 
Secondmy alld intermediate end-points Many trials have only secondary and 
intermediate end points rather than the outcome that is the one of ultimate clinical 
interest. Simvastatin, for example, has been marketed since 1989 in The Netherlands 
for reducing serum cholesterol levels. Since a high serum cholesterol concentration is 
associated with an increased risk of atherosclerosis and cardiovascular disease, it was 
suggested that simvastatin would result in decreased morbidity and mortality. 
However, it was not before 1994 that it was demonstrated, in a large placebo-
controlled trial in patients with coronary artery disease, that simvastatin indeed 
reduced mortality (58). 
Randomization /wt always optimal The concept of randomization in the conduct of 
clinical research was introduced by Sir Austin Bradford Hill. His streptomycin trial in 
tuberculosis, published in 1948, may be considered as one of the first randomised 
clinical trials (59). In the same year, the first randomised clinical trial was published 
in The Netherlands (60). Although the aim of randomization is to create prognostically 
comparable groups at baseline (61), it has been shown by Altman and Dore in a 
review of 80 published reports of randomised clinical trials, that this is not always 
achieved (62). They found a statistically significant difference in one or more baseline 
variables in 37 % of the trials. Schulz et al. (63) reviewed 206 reports of trials 
published during 1990 and 1991 in 4 obstetrics and gynaecology journals. Only 66 
(32 %) of the trials reported on how the randomization was technically achieved. 
Not all tests can be done During the clinical trials only a limited number of 
(laboratory) tests can be done. In particular type B adverse reactions to drugs, for 
example deafness by an antibiotic, will not be observed. 
Blilldillg lIot always possible Blinding means no knowledge about the treatment which 
is given, and Can be single (only the patient does not know) or double (both the patient 
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and the physician do not know). The objective of blinding is to achieve comparability 
of extraneous effects and allow unbiased outcome assessment. However, in several 
trials it is not possible or very difficult to blind. An example is the randomized trial on 
thrombolysis versus PTCA for treatment of acute myocardial infarction (64, 65). 
Moreover, while blinded in theory, for many studies the effectivenes of blinding may 
be questioned. 
Because of the limitations of clinical trials, the results of these trials may differ from 
the effects of a drug under every-day circumstances. For that reason it is always 
important to follow a drug after marketing. 
2.6 Methods of postmal'keting surveillance 
There are several aims of postmarketing surveillance, which are sunmlarized in table 
2. 
TABLE 2 
Selected objectives of postmarketillg surveillallce 
- Risk-benefit assessment 
- Assessment of effects of drugs in specific (sub-)groups 
- Detection of unknown (rare) adverse reactions 
- Estimation of the incidence of adverse reactions 
- Detection of risk factors for development of adverse reactions 
- Translation of 'secondary end points' to primary ones 
- Comparison of different drugs with tlle same indication 
- Assessment of patterns of drug utilisation 
- Study of effects of overdoses 
- Economic evaluation of pharmaceuticals 
Until now, most of the attention in postmarketing surveillance has focused on 
unintended drug effects, especially the discovery of (rare) unknown adverse reactions, 
or the assessment of the incidence of these adverse reactions. In postmarketing 
surveillance, many epidemiological techniques have been developed, resulting in a 
discipline which is now called pharmacoepidemiology. Although several methods in 
pharmacoepidemiology can be distinguished, all are, in fact, identical to the methods 
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used in epidemiology in general. The most important research approaches are 
sununarized in table 3. 
TABLE 3 
Most importallt research methods ill pharmacoepidemiology 
- Case reports & case series 
- Clinical trial 
- Cohort study (non-experimental) 
- Cross-sectional study 
- Case-control study 
- Analyses of secular trend 
More information on these designs can be obtained from any textbook of epi-
demiology. 
In pharmacoepidemiology, several systems are used to obtain empirical data (table 
4) of which some are briefly discussed below. 
TABLE 4 
Selected systems IIsed ill pharmacoepidemiology 
- Spontaneous reporting schemes 
- Intensive Medicines Monitoring Programme 
- Prescription-event monitoring 
- Record linkage systems 
- Field studies 
a. Spontaneolls reporting scilemes 
Spontaneous reporting schemes are considered an efficient means to rapidly identify 
new and rare adverse reactions (66). 
Single case reports are frequently criticized as not being substantial enough to 
reveal a new drug-safety problem. However, the potential impact of a published single 
case report has been shown by Venning, who demonstrated that most of the major 
adverse reactions to drugs were first spotted by means of case reports (67). Also, 
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publication in a medical journal is likely to attract more attention among doctors than 
the submission of a report to a manufacturer or dl1lg regulator. 
Spontaneous reporting systems have several advantages. They are relatively 
inexpensive, cover all dl1lgs used by the entire popUlation, and can rapidly react to a 
signal. The major disadvantage is (selective) underreporting. The reporting rate shows 
large differences between different countries (68). Another problem in reports on 
adverse reactions, concerns the assessment of the causal relationship between the use 
of a dlUg and a possibly associated adverse event. It has been demonstrated that even 
with standardized procedures agreement between different observers is difficult (69). 
Furthermore, among the national spontaneous reporting schemes different methods are 
used in causality assessment (70). In general, especially adverse reactions with a clear 
temporal relationship with use of the drug can be observed with this approach. 
As a reaction to the thalidomide disaster, the Netherlands Centre for Monitoring of 
Adverse Reactions to Dl1lgs (NARD) was founded in 1963 as a collaborative initiative 
of the Dutch Medical Association, the Inspectorate for Pharmaceuticals and the 
Medical Inspectorate (71). The most important objective of the centre is to discover 
unknown adverse reactions at an early stage in order to prevent an epidemic of drug-
induced injury. 
b. Intensive Monitoring 
In 1966, Hershel Jick and Demlis Slone started a system in which large numbers of 
medical inpatients were monitored continuously in order to determine the fi'equency of 
adverse reactions in these patients. This system was called the Boston Collaborative 
Drug Surveillance Program (72). 
In 1977 the Department of Health in New Zealand established a novel system: 'The 
Intensified Adverse Drug Reaction Reporting Scheme', now entitled 'Intensive 
Medicines Monitoring Programme' (IMP). Several specific dl1lgs are in this system 
selected for 'intensive monitoring' mainly because they are newly registered drugs or 
because of important serious spontaneous reports. The IMP has two parts. Firstly an 
intensified spontaneous 'event' reporting component, and secondly a cohort formation 
of users of the dlUg of interest. 
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c. Prescription-event monitoring 
Prescription-event monitoring (PEM) was developed in 1980 by the Dl1lg Safety 
Research Unit (DSRU) in the UK as a novel national approach for the detection of 
adverse events occurring during drug treatment (73). In PEM the patient, dl1lg and 
doctor are identified from the prescriptions gathered by the Prescription Pricing 
Authority (PPA). Thereafter, simple questionnaires (green forms) are posted to the 
prescribing doctors 6 to 12 months after the prescription has been written, about all 
'events' that happened since the prescription and some other information, such as age 
and diagnosis. And although the majority of reported events are in fact not adverse 
dl1lg reactions (but rather related to the disease being treated or co-incidental), it is a 
useful approach, especially for recently marketed 'new chemical entities'. However, 
the frequency of adverse reactions may be underestimated if only records of general 
practitioners are used. An example of this phenomenon in PEM was the estimated 
frequency of cough with enalapril (74, 75) as suggested by Waller (76). A number of 
studies from PEM has been published (77, 78). 
d. Record linkage systems 
In a record linkage system, data concerning both dl1lg use and morbidity are linked on 
an individual patient level. Many studies have already been performed with such 
record linkage systems. An example of a record linkage system is the Dutch 
PHARMO system (79). Several studies have been published with data from the 
PHARMO system (80), and more results are awaited. 
However, although in 1986 it was stated that 'the future of pharmacoepidemiology 
lies in record linkage' (81), others have demonstrated several limitations of automated 
record linkage systems (82). 
e. Field studies 
According to Rothman, field studies differ from clinical trials 'in that they deal with 
subjects who have not yet gotten disease and therefore are not patients' (83). As a 
consequence, all (clinical) data must be collected 'de novo' without clinical source 
documents. In postmarketing surveillance, field studies usually address a study 
population using a specific drug of interest (for instance acitretin or sumatriptan) or a 
study population with a specific (rare) disease (for instance primary pulmonary 
hypertension), permitting a cohort or a case-control study respectively. 
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Field studies have several disadvantages. In particular they are expensive and take 
a long time for completion. However, they may provide important information, which 
is not readily available from spontaneous reporting schemes or record linkage systems. 
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PART II 
REPORTS TO A NATIONAL VOLUNTARY REPORTING SCHEME 

CHAPTER 3 
THE NETHERLANDS CENTRE FOR MONITORING OF 
ADVERSE REACTIONS TO DRUGS 
Ned Tijdschr Geneeskd 1993;137:1784-7. 
Ned Tijdschr Geneeskd 1994;138:2110-13. 
Introduction 
The potential power of a published case report has been shown by Velllling, who 
demonstrated that most of the major adverse reactions to drugs were first spotted in 
this way (1). While a publication in a medical journal is likely to attract more attention 
among doctors than the submission of a report to a manufacturer or drug regulator, 
there are also limitations to published reports as a single source of information. 
Publications in the literature, however, often omit important information (2), depend 
on editorial decisions, are a very sinall proportion of the observed adverse reactions 
seen in clinical practice, and are not systematic (3). 
Spontaneous reporting schemes are considered a valuable tool to rapidly identify 
new and rare adverse reactions (3). In this chapter, some characteristics of the 
Netherlands Centre for Monitoring of Adverse Reactions to Drugs are discussed. 
Methods 
As a reaction to the thalidomide disaster, the Netherlands Centre for Monitoring of 
Adverse Reactions to Drugs (NARD) was founded in 1963 as a collaborative initiative 
of the Dutch Medical Association, the Inspectorate for Pharmaceuticals and the 
Medical Inspectorate (4, 5). Since 1963, the NARD has been a subunit of the 
Inspectorate for Pharmaceuticals of the Ministry of Health and Environmental 
Hygiene, currently the Ministry of Public Health, Welfare and Sports. The objective 
of the centre is to discover unknown adverse reactions at an early stage in order to 
prevent an epidemic of drug-induced injury. In particular, the reporting is encouraged 
of (6): 
- unknown adverse reactions 
- adverse reactions of new drugs (especially new chemical entities) 
- serious adverse reactions 
- confirmed adverse reactions (e.g. by rechallenge) 
All reports are evaluated by a medical officer and discussed during monthly meetings 
of the Adverse Reaction Advisory Conunittee. This committee supports the NARD in 
particular for auditing the causal relationship between drug exposure and the potential 
adverse reaction. Assessment of the causal relationship is based on the temporal 
relationship between drug use and onset of the adverse reaction, pharmacological 
potential of the suspected drug(s), exclusion of other possible causes of the adverse 
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reaction, and the results of re-exposure (=rechallenge) (7). The received reports are 
classified into one of the following categories of likelihood of the causal relationship 
between use of the suspected dmg and the adverse reaction: 
- Certain 
- Probable 
- Possible 
- Unlikely 
- Unclassified 
This concerns a well-documented report of an objective adverse 
reaction, with a clear temporal relationship, and with a positive 
rechallenge. All other causes have been excluded. 
Also well-documented, but without a rechallenge. All other 
causes have been excluded. Also subjective reactions with a 
rechallenge 
This classification varies between 'nearly probable' and 'not 
impossible'. Also used if two or more dmgs are suspected. Often, 
other causes are not sufficiently excluded. 
A report in which another cause than the suspected dmg is a 
more likely cause of the reaction. 
A report with incomplete (e.g. as to age or gender) or conflicting 
data. Also congenital malformations, or overdoses. 
The NARD participates in the monitoring program of the World Health 
Organization's Collaborating Centre for International Adverse Reaction Monitoring in 
Uppsala, Sweden, and routinely exchanges information with this centre which gathers 
spontaneously reported data from many countries all over tlle world. Furthermore, 
information on adverse reactions to drugs by the NARD is given directly by 
telephone, by publication in the medical literature, by advising the Dutch Medicines 
Evaluation Board to inclnde an adverse reaction into the data sheet, and by 'Dear 
Doctor' letters. 
The data 
In September 1964 the first reports were received, finally resulting in a total of 377 
reports in 1964 (8). In 1965, 362 reports were received, whereas in 1966 172 reports 
were received by the Centre. The annual number of reports between 1964 and 1995 is 
depicted in figure 1. 
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Figure 1 " Reporls received by Ihe Nelherlands Celllre 
As is demonstrated, especially since 1992, there has been a strong increase in the 
annual number of reports. Several examples of adverse reactions to drugs which were 
published in the international literature are shown in the table. 
TABLE 
Examples of adverse reactions to drugs published in the ill/emotional medical literatllre by 
the Netherlands Centre for Monitoring of Adverse Reactions to Drugs in recent years 
Drug 
Omeprazole 
Paroxetine 
Nicotine patches 
Trazodone 
Sumatriptan 
Terbinafine 
Nicotine patches 
Itraconazole 
Diclofenac 
Benzbromarone 
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Adverse reaction 
Agranulocytosis 
Bleeding risk 
Myocardial infarction 
Agranulocytosis 
Myocardial infarction 
Taste loss 
Atrial fibrillation 
Hepatic injury 
Myonecrosis 
Hepatic injury 
In 1993, the Netherlands centre received 1585 reports (9), compared to 1248 in 1992 
(10). The causality of the Dutch reports was: certain 2.5 %, probable 30.3 %, possible 
43.8%, unlikely 4.2%, and unclassified 19.2%. Of the reports, 55% were received 
from general practitioners. 232 reports (14%) were received from the pharmaceutical 
companies. Of the latter reports, the causal relationship of 107 reports (46%) was 
classified as "unlikely" or "unclassified" which was a significantly larger fraction than 
the reports from medical practitioners (p < 0.001). 
Examples of letters sent by the Inspectorate in 1995 concerned the indication 
restriction of ibopamine and the risk of thromboembolism in users of desogestrel or 
gestodene containing oral contraceptives. 
Discussion 
The Netherlands Centre for Monitoring of Adverse Reactions to Drugs suffers from 
tlle limitations shared by all spontaneous reporting systems, i.e. underreporting and 
false-positive reporting. In comparison with other countries, such as Sweden and the 
United Kingdom, there appears to be considerable underreporting in the Netherlands 
(11). It has been shown for general practice in the UK that important reasons for not 
reporting an adverse reaction are the fact that the adverse effect is well-known or 
trivial, insecurity about the causal relationship, and a lack of feedback from the 
monitoring centres (12, 13). The NARD has in the past years used several methods to 
stimulate reporting. It is attempted to increase the feed back both to reporters (by 
telephone or letter) and to all health care professionals by publishing reports in the 
medical literature. Maybe as a result of this, the annual number of reports has 
increased to a total of 1750 in 1994. 
The increase in the annual number of reports is remarkable, since in The 
Netherlands a regional reporting system has also existed since 1984 (14). In 1987, it 
was demonstrated that the NARD received relatively more serious and more well-
documented reports than this regional system. The increase of the number of reports 
to the NARD endorses, however, the possibility that health care professionals prefer 
to report to a national centre within the Ministry of Health. Hence, it seems to be 
important that a reporting centre will remain in the vicinity of the Ministry. 
Causality assessment in the reports was performed on the basis of previously 
published criteria (7). It has, however, been suggested that there is often 
misclassification, and that in general in most reports the causal relationship between 
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the drug and the event is no more than 'possible' (16). 
The new regulations in Europe concerning reporting adverse reactions to drugs (17) 
will result in a growing number of reports from pharmaceutical companies. The 
reports to the NARD show, however, that these reports are significantly more 
frequently 'unclassified' or 'unlikely'. If this means that these reports are more often 
less well documentated or more often concern utll'elated 'events' this is not a 
favourable development. Maybe, education of drug safety officers of pharmaceutical 
companies may improve these reports. 
In conclusion, since 1963 the Netherlands Centre for Monitoring of Adverse 
Reactions to Drugs (NARD) has been responsible for a nationwide spontaneous 
reporting scheme. In recent years, an increase in the annual number of reports to the 
centre was observed, resulting in a total of 1750 reports in 1994. In the future, it is 
not only important to increase the annual number of reports, but also to improve the 
quality of the reports, in particular those from pharmaceutical companies. 
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CHAPTER 4 
DRUG-INDUCED CHEST PAIN AND MYOCARDIAL 
INFARCTION: REVIEW OF REPORTS TO A 
NA TlONAL CENTRE 
submitted 
Introduction 
Research on adverse reactions to drugs is an issue of growing professional and public 
interest. Because serious adverse reactiom; to drugs are often rare, they are difficult to 
detect and to investigate. In spite of the low incidence, it is important to recognize drugs 
as the cause of serious illness. Firstly, if dmgs are used for minor ailments, even a low 
incidence of a serious adverse reaction may unfavourably affect the benefit/risk ratio. 
Secondly, timely recognition of dmgs as the cause of disease, and subsequent 
discontinuation may be life-saving. Finally, knowledge on adverse dmg reactions may 
help to identify groups of patients at particular risk. 
The different adverse effects of dmgs on the heart, are summarized in table 1. 
TABLE 1 
Differellt adverse effects of drugs all tlze heart 
Arrhythmias and conduction disorders 
Heart failure 
- Direct: Negative inotropism Of chronotropism 
- Indirect: Salt and water retention 
Myocardial ischemia/infarction 
- Direct: Reduced coronary blood flow. thrombosis 
- Indirect: Coronary 'steal', interaction with anti-anginal drugs 
Pericardial disease 
- Hemopericarditis 
- Others 
The commonest way in which dmgs adversely affect the function of the heart is by the 
production or aggravation of cardiac arrhytlmlias or conduction disorders. The next most 
common adverse effect of dmgs on the heart is the initiation or aggravation of heart 
failure. Less frequently, drugs may cause myocardial ischemia or infarction, or may 
make the patient more susceptible to these disorders. 
Although voluntary reporting systems have several disadvantages, especially 
underreporting, they have fundamental value in detecting and characterising rare adverse 
dmg reactions (1, 2). In this paper, we present an analysis of the reports on drug-
induced chest pain and myocardial infarction, received by the Netherlands Centre for 
Monitoring of Adverse Reactions to Drugs between January 1st 1975 through December 
31st, 1994. 
Methods 
The Netherlands Centre for Monitoring of Adverse Reactions to Drugs (NARD) holds a 
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nationwide voluntary reporting scheme for adverse reactions to drugs. All reports are 
evaluated by a medical officer and discussed at monthly meetings of the Advisory 
Board. All reports received by the NARD between January 1st 1975 tln'ough December 
31st 1994 concerning drug-induced chest pain, myocardial ischemia or infarction were 
included in this study. Only adverse drug reactions due to drugs in therapeutic doses 
were considered. All reports came from general practitioners, specialist doctors or 
hospitals. Minimally requested were data about the age and sex of the patients, dose and 
duration of the suspected drug, and clinical signs and symptoms. Each report was 
evaluated carefully, whereafter the likelihood of a causal relationship was assessed 
between use of the suspected drug(s) and the symptoms. Evaluation of potential causality 
of the relationship was based on the temporal relationship of the adverse reaction, 
pharmacological potential of the suspected drug(s), exclusion of other possible causes of 
myocardial ischemia, such as coronary stenoses, and the results of re-exposure 
(=rechallenge) (3). A causal relationship was considered 'unclassified' or 'unlikely', 
respectively, when too few data were available or when more likely causes were found. 
In the analysis, reports were excluded if the causal relationship was unlikely or 
unclassified. 
Acute myocardial infarction was considered to be present if at least two of the 
following criteria were present: I) A recent positive clinical history of chest pain of at 
least 30 minutes; 2) Characteristic changes in the electrocardiogram; 3) Peak elevation 
of serum enzymes (CPK, SGOT) of at least 2 times the upper limit of normal. 
Differences between group means were tested by two-tailed Student's t test. A chi-
square statistic was calculated to test differences between proportions. Statistical 
significance was defined as a p-value of less than 0.05. 
Results 
The Netherlands Centre for Monitoring of Adverse Reactions to Drugs received during 
the study period a total of 19,141 reports on adverse reactions to drugs. Of these 
reports, 220 (1.1%) concerned reports of drug-induced chest pain or myocardial 
infarction. 22 reports (10%) were poorly documented and of 15 reports (6.8%) the 
causal relationship was unlikely. The poorly documentated reports, and the reports in 
which the causal relationship was unlikely were excluded from further analysis. Three 
reports, on myocardial infarction to sumatriptan, nicotine and sulprostone respectively, 
were previously reported in the literature as a case-report (4). 
The 183 reports which were suitable for analysis, concerned 103 females (56%) and 
80 males (44%), with an average age of 51 years. In table 2 an overview is given of the 
suspected drugs. 
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TABLE 2 
Ol'erl'iew oj drugs which were related to chest paill or myocardial illjarction in I83 reports' 
Drug-group (number of reports) 
Cardiol'ascular (37) 
Ca-antagonists (15) 
ACE-inihibitors (6) 
n-blockers (5) 
cd -blockers (2) 
Other (9) 
Celltral nerl'ous system (53) 
Antidepressants (17) 
Antipsychotics (1) 
Anti-migrainous (35) 
Respiratory system (IS) 
fi-mimetics (7) 
Antihistamines (5) 
Other (3) 
Hormolles (12) 
Allti-injectives (IS) 
Antibiotics (10) 
Others (6) 
Allalgesics (10) 
Gastro-intestinal drugs (5) 
Miscellaneous (44) 
Drug (number of reports) 
Nifedipine (9), diltiazem (4), verapamil (2) 
Captopril (I), lisinopril (2), perindopril (2), enalapri! (I) 
Oxprenolol (I), pindolol (I), atenolol (I), metoprolol (2) 
UrapidU (1), prazosin (I) 
Diuretics (7), ibopamine (I), disopyramide (1) 
Imipramine (1), amitriptyline (2), mianserin (I), 
moclobemide (4), fluvoxamine (2), trazodone (2), 
fluoxetine (3), maprotiline (I), doxepine (1) 
Clozapine (1) 
Ergotamine (I), sumatriptan (33), methysergide (1) 
Salbutamol (3), salmeterol (4), formoterol (2) 
Terfenadine (1), cetirizine (2), cinnarizine (2) 
Theophylline (I), beclomethason (I), noscapine (1) 
Oral contraceptives (4), oestrogens (3), 
sulproston (I), epoetin (I), desmopressin (3) 
Nitrofurantoin (4), co-trimoxazol (I), amphotericin (1), 
amoxicillin (I), metronidazole (1), norfloxacin (I) 
mefloquine (3), niridazole (2), ketoconazole (I) 
NSAlDs (6), glafenine (2), penicillamine (1), aspirin (I) 
Cisapride (2), cimetidine (2), domperidone (1) 
Alfuzosin (3), nicotine (9), amphetamines (2), fen-
fluramine (2), fi-blocker containing eye drops (4), various (24) 
* In 9 reports more than one drug was suspected 
There were 130 reports (71 %) of drug induced chest pain and 53 reports (29%) of drug 
induced myocardial infarction. Of the 130 patients with chest pain attributed to use of 
drugs, 40 patients (31 %) had a positive rechallenge after renewed exposure to the drug. 
Compared to drug-induced chest pain, drug-induced myocardial infarction was more 
frequently reported in males (63% vs. 35%; p < 0.001). 18 patients (9.8%) died after 
myocardial infarction. Age was not related to myocardial infarction or death. Only in a 
few patients with drug-induced chest pain was an ECG performed, but by the time tllis 
was done, in almost every patient the chest pain had already disappeared. In 6 patients 
abnormal ECGs were observed. 
In 174 out of 183 reports, one drug was suspected to have caused the adverse 
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reaction, whereas in 5 reports two dtugs were suspected and in 4 reports more than two 
drugs were suspected. Chest pain or myocardial infarction were attributed to a total of 
98 different drugs. The drugs most frequently reported were sumatriptan (33 reports), 
nicotine (9 reports), nifedipine (9 reports), diltiazem (4 reports), moclobemide (4 
reports) and salmeterol (4 reports). 
There were several reports of chest pain or myocardial infarction attributed to the use 
of cardiovascular drugs. 15 reports concerned calcium-chatUlel blocking agents: 9 
reports concerning nifedipine (7 chest pain, 2 acute myocardial infarction), 4 reports 
concerning diltiazem (all chest pain) and 2 reports concerning chest pain attributed to use 
of verapamil. There were 3 reports of chest pain induced by systemic use of Il-blockers 
(oxprenolol, pindolol and atenolol). ACE-inhibitors were suspected in 5 reports: 
captopril (1 report of chest pain), lisinopril (1 report of chest pain, 1 report of 
myocardial infarction) and perindopril (1 report of chest pain, 1 report of myocardial 
infarction) . 
There were 17 reports of chest pain or myocardial infarction attributed to use of 
antidepressants. Three of them concerned fatal myocardial infarction after use of 
tricyclic antidepressants (1 imipramine, 2 amitriptyline). These concerned 2 females and 
one male. Four reports concerned myocardial infarction attributed to use of the MAO-A 
inhibitor moclobemide, of which two concerned a fatal reaction. 
Several reports concerned chest pain or myocardial infarction attributed to drugs for 
respiratory problems, of which 7 reports concerning Il-mimetics are of special interest. 
These comprised 6 reports of myocardial infarction and 1 report of chest pain attributed 
to salbutamol (4x), salmeterol (3x) or formoterol (2x) (in two reports both salmeterol 
and salbutamol were suspected). These reports concerned 7 males with a mean age of 49 
years. 
Four reports concerned adverse reactions attributed to use of oral contraceptives (two 
myocardial infarction, two chest pain), whereas in 3 reports chest pain or myocardial 
infarction was attributed to other oestrogens. One report concerned a myocardial 
infarction due to intravenous administration of sulprostone. Three reports concerned 
chest pain (one report) or myocardial infarction (two reports) attributed to desmopressin. 
There were two reports of acute myocardial infarction and one report of chest pain 
attributed to use of alfuzosin. One report concerned a 53-years-old male, who 
experienced severe angina pectoris within one hour after intake of the first tablet of 
alfuzosin 2.5 mg. He was admitted to a hospital, and a diagnosis of acute myocardial 
infarction was made. This patient had never had chest pain before use of alfuzosin, and 
a causal relationship seems probable. 
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Discussion 
The most common cause of myocardial ischemia is coronary artery sclerosis and 
stenosis, whereas an acute myocardial infarction is mostly caused by occlusive thrombi 
in atherosclerotic coronary arteries. Transmural myocardial infarction with 
angiographically normal coronary arteries is rare (5) and has been associated with a 
defect of fibrinolysis (6), early age (7), cigarette smoking (8) and drug use. Especially 
in patients with chest pain or myocardial infarction and normal coronary arteries it is 
important to consider drugs as a potential cause of the complaints. 
Although the incidence of acute myocardial infarction due to drug-induced ischemia 
is probably low, there are several reasons why it is important to know which drugs can 
induce myocardial ischemia, and which mechanism is involved. Firstly, drugs can be 
identified which should be used cautiously, especially in patients with coronary artery 
disease. Secondly, it is important to comider a cardiac origin if chest pain occurs in a 
patient' using some specific drugs, in particular if it is a patient without any reason to 
suspect a cardiac origin of the complaints, for example, a young female. Under certain 
circumstances, discontinuation of a specific drug may prevent myocardial infarction and 
may be life-saving. Thirdly, in patients diagnosed as having myocardial infarction or 
angina pectoris with normal coronary angiography, the possibility of an association with 
the intake of some drugs should be comidered. Fourthly, the diagnostic and therapeutic 
approach of patients with drug-induced myocardial ischemia or infarction may differ 
from patients with regular myocardial ischemia or infarction. Finally, the 
pharmacological mechanisms may also provide insight into the pathophysiology of 'not-
drug-induced' myocardial ischemia. 
Cardiovascular drugs 
There were several reports of chest pain or myocardial infarction after use of 
cardiovascular drugs. Especially interesting were 15 reports of chest pain or myocardial 
infarction attributed to calcium-antagonists. Recently, in a case-control study of 
hypertensive patients a relatively higher risk of myocardial infarction was found in 
patients taking calcium antagonists (9). In a meta-analysis by Furberg et ai, a dose-
dependent association of use of nifedipine with mortality was observed (10). Since 
hypertension is associated with both myocardial infarction and mortality, these 
associations are explained by some as a result of confounding by indication (11). 
Confounding by indication can even result in a dose-dependent association. There are, 
however, several case-repOlts in which a relatiomhip between administration of 
nifedipine and aggravation of myocardial ischaemia Was observed (12, 13). 
There were 3 reports of chest pain induced by systemic use of (I-blockers 
(oxprenolol, pindolol and atenolol), and 4 reports of chest pain induced by (I-blocker 
containing eye drops (timolol 2x, betaxolol, metiprallolol). Acute myocardial infarction 
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has been associated with propranolol (14) and metoprolol (15). Also B-blocker-
containing eye drops have been associated with chest pain (16) and myocardial infarction 
(17). The pathophysiologic mechanism of B-blocker induced myocardial ischemia is 
probably coronary vasospasm mediated by alpha-adrenergic receptors (15). 
A few reports concerned chest pain or myocardial infarction attributed to use of ACE 
inhibitors. In the literature, several case reports of angina pectoris related to captopril 
have been published (18, 19). 
Central nervous system 
There were three reports of fatal myocardial infarction, attributed to tricyclic 
antidepressants. This is especially of interest, because recently in a case control study an 
unexpected 6-fold increase in risk was demonstrated of fatal myocardial infarction in 
young women associated with current use of tricyclic antidepressants (20). In general, 
the cardiovascular effects of tricyclic antidepressants are considered to consist mainly of 
conduct disturbances, arrhytlllllias and orthostatic hypotension (21, 22). Myocardial 
infarction was attributed to moclobemide in four reports. Recently, hypertension was 
described as an adverse reaction of this MAO-A inhibitor (23). 
Anti-migrainous drugs 
In the literature, there have been several reports of cardiac ischemia due to the 
anti migrainous drugs ergotamine (24, 25), methysergide (26), sumatriptan (27) and 
isometheptene (28). The proposed mechanism is coronary spasm. There was a large 
number of reports to our centre of chest pain (29 reports) and several reports (four) of 
myocardial infarction attributed to use of the new anti-migrainous drug sumatriplan. One 
report of myocardial infarction (29) and 13 reports of chest pain (30) were pUblished in 
the literature as case reports. In clinical trials, the frequency of cliest pain after use of 
sumatriptan was approximately 5% (31, 32), whereas in a postmarketing study the 
frequency was estimated to be 8 % (33). Furthermore, several cardiac adverse reactions 
have been associated with use of sumatriptan in the literature (27, 34, 35). It is, 
however, not yet known whether the frequency of cardiac adverse reactions to 
sumatriptan is more frequent than to ergotamine. 
Respiratory system 
There were six reports of myocardial infarction and one report of chest pain attributed to 
use of B-mimetics and one report of myocardial infarction attributed to theophylline. In 
the literature, acute myocardial infarction following both intravenous and inhaled 
treatment with salbutamol has been described (36, 37). An increase of mortality in 
regular users of ll,-agonists has been demonstrated, but drug-induced myocardial 
ischaemia is not considered to be one of the mechanisms (38). A case report of a patient 
who experienced a myocardial infarction attributed to use of theophylline was previously 
published (39). Furthermore, it has been demonstrated that theophylline can cause 
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tachycardia and myocardial ischemia, even at recommended doses (40). However, since 
cardiac and respiratory disease commonly co-exist (and have several risk factors in 
common such as smoking) the causal implications remain difficult to assess. 
Hormones 
There were two reports of myocardial infarction during use of oral contraceptives. In 
fact, this potential association can not be clarified by case reports, since there is a lack 
of clear temporal relationship. In a case-control study Thorogood et al demonstrated that 
current users of oral contraceptives had an increased, although not statistically 
significant, risk of fatal myocardial infarction (41). 
In two reports of myocardial infarction and in one report of chest pain, the reactions 
were attributed to use of desmopressin. This association has previously been described in 
the literature (42). 
Analgesics 
Coronary spasm has been described after use of naproxen (43) and glafenine (44). The 
proposed mechanism is an allergic reaction (43). 
Miscellaneous 
Of the reports to the national centre of chest pain (n=4) or myocardial infarction (n=5) 
attributed to use of nicotine, one was previously published as a case report (45). There 
have been reports of serious cardiovascular adverse reactions in literature, including 
acute myocardial infarction and cardiac arrest, associated with continued smoking during 
use of the patches (46-48). 
There were two reports of acute myocardial infarction and one report of chest pain 
attributed to use of alfuzosin. Alfuzosin is a relatively new drug, used for the 
symptomatic treatment of benign prostatic hyperplasia, which acts as an antagonist of 
cd -adrenoceptors (49). According to the close temporal relationship with intake of 
alfuzosin, the relationship between use of this drug and the adverse reactions seems to 
be probable. Alfuzosin is, however, often prescribed in patients with a high risk for 
coronary diseases (elderly males). There were also reports on two other cd-blockers, 
urapidil and prazosin, which were used for hypertension, concerning chest pain 
attributed to use of these drugs. 
Two reports concerned chest pain attributed to use of fenfluramine. Myocardial 
infarction associated with dexfenfluramine has been described previously (50). 
Underreporting and selective reporting 
The most important disadvantages of a spontaneous reporting system are underreporting 
and selective reporting. According to the latter, it is in particular interesting that chest 
pain or myocardial infarction was in not even one report attributed to cytostatic drugs, 
blood coagulation factors or cocaine. 
Malignancy may affect the heart by direct invasion as in lymphoma, or by blood 
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borne metastases as in malignant melanoma (51). Moreover, several antiproliferative 
drugs and/or irradiation to the mediastinum can cause cardiac damage (52-54). These 
drugs include 5-fluorouracil (55), taxol (56), bleomycin and etoposide (57) and cisplatin 
(58). 
Several cases of myocardial infarction attributed to the administration of blood 
coagulation factors have been documented in the literature (59-61). In most cases, 
patients with haemophilia were involved. 
Cases of cocaine-induced myocardial infarction were previously reviewed in the 
literature (62). 
Conclusions 
The present study demonstrated the reports of drug-induced chest pain or myocardial 
infarction as reported to the Netherlands Centre for Monitoring of Adverse Reactions to 
Drugs during the period 1975 through 1994. The reviewed reports give an impression of 
the different drugs and the different mechanisms in the difficult field of dnlg-induced 
myocardial ischemia or infarction. 
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CHAPTER 5 
ADVERSE REACTIONS TO SUMATRIPTAN: 
REPORTS TO THE NETHERLANDS CENTRE FOR 
MONITORING OF ADVERSE REACTIONS TO DRUGS 

CHAPTER 5.1 
CHEST PAIN ATTRIBUTED TO SUMATRIPTAN 
Ned Tijdschr Geneeskd 1992;136:1774-6. 
Introduction 
Sumatriptan is a selective serotonin-I agonist which was registered in May 1991 in the 
Netherlands. As a result of this registration, the Netherlands was the first country in 
the world where this drug, used in the treatment of acute attacks of migraine and 
cluster headache was marketed. In premarketing research it was already observed that 
use of sumatriptan may lead to feelings of 'heaviness' in several parts of the body, 
which can be accompanied by chest tightness. 
The Netherlands Centre for Monitoring of Adverse Reactions to Drugs received 13 
reports, demonstrating that these complaints can resemble the clinical picture of an 
acute attack of angina pectoris, with chest pain radiating to the throat and left arm. 
The British Committee on Safety of Medicines recently received 34 similar reports 
after subcutaneous administration of sumatriptan (I). 
Case histories 
Since the registration of sumatriptan (Imigran) in May 1991, until June 1992, the 
Netherlands Centre for Monitoring of Adverse Reactions to Drugs received 13 reports 
of substernal chest tightness or pain attributed to its use (table). These concerned 
eleven females and two males with an average age of 41 years (range 19 to 61 years), 
who all developed angina-like symptoms. The onset of symptoms was in almost all 
patients within one hour after administration of sumatriptan. In particular after 
subcutaneous adminstration a close and immediate temporal relationship was evident. 
Symptoms varied from substernal tightness to severe cramping angina-like pain 
radiating to the left arm and hand. In one patient a transient increase in blood pressure 
to 200/120 mm Hg was noted, which later fell to 160190 mm Hg. Three patients had 
complaints of dyspnoea, without signs of bronchospasm or laryngospasm. Five 
reporting medical practitioners classified the symptoms as anginal, and tlu'ee of them 
notified these as 'classical' or 'real' angina pectoris. In all patients, symptoms 
resolved without further treatment. Most patients also used concomitant drugs (table), 
but only one patient used a cardiovascular drug (isosorbide dinitrate). Propranolol and 
clonidine as used by patient Hand L respectively, were both used as a prophylaxis in 
the treatment of migraine. 
Electrocardiograms (ECG) were normal in cases C, E and H, but were obtained 
after the chest symptoms had resolved. In the other patients no ECG was performed. 
An echocardiogram and results of an exercise test performed after the first episode of 
62 
TABLE 
Details of 13 cases of chest pain after sumatrtipan as reported to the Nether!ands Centre for Monitoring of Adverse Reactions 
to Drugs between May 1991 and June 1992 
Case Age/sex Dose and route Latent period Symptoms Recurrence after Other drugs 
(minutes)' rechallenged 
A 36, F 100 mg orally 30 - 45 Substernal pressure, ND Terfenadine 60 mg 
drowsiness, nshaky" 
B 38, F 100 mg orally 30 Substernal pressure and > 10 times Carbamazepine 600 mg, !actulose, 
pressure in the shoulders/neck hydroquinone hydrobromide dihydrate 
C 61, F 100 mg orally Same day Anginal pain radiating to 2 times Isosorbide dinitrate 5 mg 
the left ann 
D 46, F 100 mg orally 15 Substernal pain, sweating 3 times Oral contraceptive 
E 53, M 100 mg orally About 30 Anginal pain ND None 
F 44,M 100 mg orally 30 Substernal chest pain, ND None 
palpitations, pain in throat 
G 27,F 100 mg orally 30 Substernal chest pain, malaise, ND None 
Paraesthesia, heaviness of arms 
H 33, F 6 mg subcutaneously 1-5 Angina pectoris radiating to left 2 times Propranolol 60 mg 
arm and hand, dyspnoea 
J 45,F 100 mg orally Same day Substernal pressure, muscle ND None 
stiffness 
K 19, F 6 mg subcutaneously 30 - 60 Chest pain, dyspnoea, nausea ND Oral contraceptive 
L 50, F 6 mg subcutaneously 1 - 5 Anginal pain radiating to ND Clonidine 100 p.g, 
the jaw, hypertension aspirin 600 mg 
M 36, F 100 mg orally 30 Substernal chest tightness ND None 
N 39, F 6 mg subcutaneously 1 - 5 Angina pectoris, radiating 2 times None 
to the throat 
* Between first intake and onset of symptoms as notified by reporting doctor. # ND = Rechallenge not done. 
chest pain in case H were normal. Except for case L, who had experienced a similar 
reaction to ergotamine in the past, none of the patients had had similar episodes before 
using sumatriptan and none developed these symptoms again after stopping it. None of 
the patients had a history of cardiovascular disorders or diabetes mellitus. 
Discnssion 
According to the close temporal relation between administration of sumatriptan and 
onset of chest pain, a causal relationship between use of the dmg and the complaints 
seems to be probable in these patients. Furthermore, in five patients there was 
recurrence of symptoms after renewed exposure to sumatriptan. Other causes of chest 
pain were excluded in most patients, and most of them were young. 
Although the majority of patients was female, it would not be justified to conclude 
that females have a higher risk of sumatriptan-induced chest pain compared to males. 
Firstly, consumption patterns should be taken into account, in particular because 
females have more often complaints of migraine. Secondly, spontaneous reporting 
schemes have several disadvantages, not only of underreporting, but also of selective 
reporting. 
Unfortunately, in only few patients an EeG was performed. Because the EeGs 
were not obtained during the sumatriptan-induced complaints, but after the chest 
symptoms had resolved, it remains unclear whether EeG abnormalities were present 
during these complaints. In a recently described case history (2), chest pain within 
four minutes after subcutaneous administration of sumatriptan was accompanied by ST 
elevation on EeG, which suggests myocardial ischaemia. 
Angina pectoris and myocardial ischaemia have been described as a result of use of 
the antimigrainous drug ergotamine (3). These concern potentially serious adverse 
reactions, which can result in acute myocardial infarction (4). 
Early studies suggested that serotonin-l receptors are largely confined to the cranial 
circulation rather than to the coronary circulation. As serotonin-2 receptors are more 
common in coronary arteries than serotonln-l receptors tile effect of sumatriptan (a 
serotonin-l agonist) on coronary vasculature is considered to be relatively mild. 
Serotonin itself may cause constriction of isolated epicardial coronary arteries (7), but 
the vasoconstrictive effect of sumatriptan has been estimated to be only 30 % of 
serotonin (5). In general, this should not lead to myocardial ischaemia, but if the 
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coronary arteries have atherosclerotic abnormalities, the constriction can be more 
severe or result in a significantly reduced blood flow. The enhanced vasoconstrictive 
response of atherosclerotic isolated epicardial coronary arteries to histamine is also 
seen after administration of serotonin (7, 8). 
A study by the manufacturer of sumatriptan in 10 patients with suspected coronary 
artery disease showed an average constriction of coronary arteries of 13.9% 10 
minutes after subcutaneous administration of 6 mg sumatriptan (Glaxo, unpublished 
data). However, in this study in one patient a 60% reduction of tile diameter of the 
left anterior descending artery was observed. Although in this study mean aortic and 
pulmonary artery pressures were raised, cardiac output did not change. No 
electrocardiographic abnormalities were noted, and only one patient experienced chest 
tightness. 
Two explanations for the chest symptoms after use of sumatriptan are plausible. 
Firstly, it may be a result of direct stimulation of serotonin-l receptors in several 
organs, since in clinical trials relatively many patients experience paraesthesia and 
feelings of heaviness in several parts of their body. Another possibility is that chest 
pain is caused by myocardial ischaemia. Patients with atherosclerosis of the coronary 
arteries may be a risk group for myocardial ischaemia induced by sumatriptan. This 
seems unlikely in the patients we described, because most of them were young and 
had no history of cardiovascular diseases. However, myocardial ischaemia might 
occur as a part of variant angina with spasm of coronary arteries. 
In conclusion, sumatriptan can cause symptoms resembling acute attacks of angina 
pectoris. In the literature, a case has been reported with sumatriptan-induced chest 
pain accompanied by ST elevation on EeG, but this was a patient with a history of 
angina pectoris prior to use of sumatriptan (2). However, although sumatriptan seems 
to be an effective drug in the treatment of migraine, we advise cautious use of 
sumatriptan, especially in any patient who has chest pain or tightness after use of this 
drug, as in some patients sumatriptan may cause myocardial ischaemia or even 
myocardial infarction. It is not yet clear which patients are at increased risk of 
myocardial ischaemia to sumatriptan, but patients with coronary atherosclerosis and 
patients with a histOlY of variant angina pectoris should not use this drug, as is stated 
in the data sheet of sumatriptan 
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CHAPTER 5.2 
TRANSMURAL MYOCARDIAL INFARCTION WITH SUMATRIPTAN 
Lancet 1993;341:861-62. 
Introduction 
Sumatriptan is a serotonin-I agonist used to treat acute attacks of migraine and cluster 
headache (I). In trials, sensations of pressure and tightness in the chest occurred in 
3 % of patients treated with 100-300 mg orally and in 5 % of patients after 
subcutaneous administration of 4-8 mg, but no electrocardiographic (ECG) evidence of 
cardiac ischaemia was demonstrated (2). In postmarketing experience with 
sumatriptan, angina-like pain was noted, but a cardiac cause has not been established 
(3, 4). One patient developed chest pain with ST elevation after sumatriptan 6 mg 
subcutaneously (5). In this patient, pain subsided and the ECG returned to normal in 
22 minutes without subsequent increase in cardiac muscle enzymes. Two cases of 
serious ventricular arrhythmias have been reported after use of this dmg (6). We 
report a patient who developed acute myocardial infarction after use of sumatriptan. 
Case report 
A 47-year-old woman was admitted to hospital at 1800 h complaining of several hours 
of severe substernal pain radiating to the left shoulder and nausea without vomiting . 
She had had these symptoms since 0700 h that day, 15 minutes after she had 
administered sumatriptan 6 mg subcutaneously for an acute attack of cluster headache. 
She had had episodes of left-sided cluster headache for several years, which were not 
relieved by ergotamine. She had never experienced chest pain after use of ergotamine 
or any other drug. Her history revealed no signs of diabetes mellitus, Raynaud's 
phenomenon, hypertension, angina, or pre-existing vascular disease; she smoked ten 
cigarettes a day. She had used ranitidine 150 mg daily for an endoscopically proven 
duodenal ulcer for the past 3 months, but she used no other dmgs, including oral 
contraceptives. There was no family history of coronary heart disease. 
I week before admission she had started sumatriptan, which relieved the headache. 
But 15 minutes after administration of sumatriptan, she had chest pain for about 20 
minutes. The next day she had the same chest symptoms after the subcutaneous 
injection. I week later, on the day of admission, she again had chest pain 15 minutes 
after dmg administration, but this time chest pain did not disappear. So, in total, she 
had self-administered three doses of sumatriptan 6 mg subcutaneously. 
On admission, the patient was normotensive (110160 mm Hg), had normal 
peripheral pulses, and had no signs of congestive heart disease. ECG showed a regular 
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sinus rhythm of 60/min with a normal PQ interval. However, in leads III and a VF, 
inverted T-waves were seen, accompanied by pathologic Q waves (figure) . 
.. _- ---; . ~---:-. ., 
1-"-----' oVR· 
Il-I . 
Figure - ECG of a 47-year-old woman, admitted with several hours during 
chest pain, which started 15 mil/utes after she had administered sumotriptan 6 
mg subcutaneously for all acute attack of cluster headache. 
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Creatine kinase was 442 lUlL (normal < 100 lUlL) with an MB fraction of 20%. A 
recent transmural inferior myocardial infarction was diagnosed, and therapy with 
nitrates and heparin was started. The following day, creatine kinase had increased up 
to 873 U/L. During the next few days, the patient recovered without complications. 
A symptom-limited bicycle test 1 day before discharge demonstrated a maximum 
work-load of 95 W (normal 120 W). There was a normal increase in heart rate and 
blood pressure. The patient did not have anginal pain at any moment during or after 
the bicycle test. At maximum workload there was a 1.5 mm ST segment depression in 
lead I, V5, and V6 with slight upsloping of the ST segment. The test was regarded as 
indicative of possible ischaemia. 
Discussion 
According to both the close time relation between administration of sumatriptan and 
onset of chest pain and the recurrence of symptoms after evelY exposure, the chest 
pain in our patient was due to use of sumatriptan 6 mg subcutaneously. There is no 
doubt that the patient developed an acute transmural inferior myocardial infarction, 
after the third time that she administered sumatriptan. In view of the outcome after the 
third injection, we assume that the chest pain after the first and second injection was 
caused by reversible myocardial ischaemia. 
Postmarketing experience with sumatriptan has failed to show any evidence of 
myocardial· ischaemia in the absence of symptomatic cardiac disease (7). Willet et al 
(5) described an episode of coronary vasospasm without myocardial infarction after 
subcutaneous administration of sumatriptan. However, this patient had a history of 
retrosternal chest pain, not only in relation to methysergide and sumatriptan but also 
on awakening. Our patient had never had chest pain before she used sumatriptan. 
Coronary vasospasm and myocardial infarction after ergotamine, another 
antimigrainous dlUg, has been well documented (8, 9), but the effect of sumatriptan on 
coronary vasculature is thought to be mild (10). Our patient had, however, not 
developed chest pain after use of ergotamine. 
The case we report shows that chest pain after subcutaneous use of sumatriptan in 
patients without any history of underlying ischaemic heart disease or Prinzmetal's 
angina can result in an acute myocardial infarction. We advise cautious use of 
sumatriptan, especially in any patient who has chest pain or tightness after use of this 
drug. 
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*Oltervanger JP, StricJ<er BHCh. Smnatriptan and chest pain. 
Leiter to the editor. Lancet 1993;342:176. 
To the Editor: In their June 19 commentary about sumatriptan and chest pain (I), Dr. 
Hillis and Dr. MacIntyre suggested that our case of transmural myocardial infarction 
which we reported earlier in an issue of this journal (2), can be explained by a 
previous myocardial infarction, before administration of sumatriptan. However, we 
think that this is highly improbable. In general, the diagnosis of acute myocardial 
infarction is based upon at least two of the following criteria: I) A recent positive 
clinical history of chest pain; 2) characteristic changes in the electrocardiogram 
(ECG); or 3) peak elevation of serum enzymes (creatine kinase, aspartate 
aminotransferase, lactic dehydrogenase). We described in our case report a recent 
history of chest pain (beginning II hours before admission) with a rise in serum 
enzymes (peak values for creatine kinase at the day after admission) and changes in 
the ECG suggestive of myocardial infarction. In view of the pattern of enzyme release 
(3) and the recent history of chest pain, in our view there is no doubt that this 
concerns a recent myocardial infarction. Pattern and evolution of ECG after acute 
myocardial infarction vary among patients. The patient we described was admitted 11 
hours after onset of chest pain. It is likely that at that time an elevation of the ST 
segment did return to the baseline. 
Furthermore we think that Hillis and MacIntyre's conclusion that the coronary 
vasoconstrictive effects of sumatriptan are less than that of serotonin or the ergot 
alkaloids is premature. Firstly, their angiographic studies of sumatriptan were small 
(4, 5), and postmarketing experience with sumatriptan is much less than with ergot 
alkaloids. Secondly, whereas Hillis and MacIntyre and co-workers showed a moderate 
reduction of coronary artery diameter induced by sumatriptan in patients without 
substantial coronary atherosclerosis (4, 5), it has been demonstrated that serotonin has 
a vasodiiatolY effect on normal human coronary arteries (6). Thirdly, it is incorrect to 
compare the coronary vasoconstrictive effects of subcutaneous or intravenous 
sumatriptan in patients without coronary artery stenosis of ;::50% (4, 5), with the 
effects of illlracorollwy serotonin in patients with angina of whom most had 
substantial coronary stenoses (7). Finally, any conclusion about the comparative 
effects on the coronary artery diameter of sumatriptan and ergot alkaloids requires a 
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pharmacodynamic study with both drugs in one study population. Hence, further 
studies are warranted before an explicit statement regarding the comparative coronary 
effects of sumatriptan and ergot alkaloids is justified. 
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CHAPTER 6 
CARDIOVASCULAR ADVERSE REACTIONS TO 
SUMATRIPTAN: CAUSE FOR CONCERN? 
eNS Drugs 1995;3:90-98. 
Introduction 
Although most drugs are relatively safe (1), it is still important to consider and to 
estimate their potential risk. A drug-related problem as the primary cause of 
hospitalisation is generally estimated at approximately 5 - 10 % of all hospital 
admissions (2). Sometimes, new insights into the risk of adverse reactions lead to 
withdrawal of a drug more than 20 years after marketing (3, 4). Hence, on-going risk 
assessment cannot be omitted, not even if it concerns widely accepted drugs. For 
obvious reasons, the need for postmarketing surveillance of new chemical entities is 
even stronger. 
The serotonin-l (5HT -1) agonist sumatriptan is a relatively new antimigrainous 
dlllg, which has been registered in several European countries and in the United States 
since 1991 (5-8). It has been demonstrated that use of sumatriptan is highly effective, 
rapid-acting and well-tolerated in the treatment of acute attacks of migraine (9). 
Recently, it was stated that sumatriptan has now established itself as the gold standard 
against which other treatments of acute migraine attacks should be compared (10). 
After marketing of sumatriptan, reports were published on angina pectoris, cardiac 
arrhythmias and myocardial infarction, attributed to the use of sumatriptan. A warning 
statement about drug-related fatalities was added to the labelling of sumatriptan in 
August 1994 in the USA (11). In tllis chapter on chest pain and cardiovascular adverse 
reactions to sumatriptan, we also discuss the pharmacology and efficacy of, and the 
adverse reactions in general to sumatriptan, the association of migraine and serotonin 
with cardiovascular disease, and the differential diagnosis of chest pain. 
Migraine, cardiovascular disease and serotonin 
Migraine is a conmlon neurological disorder (12), that can severely affect quality of 
life and daily function. The disorder is more common in women and less frequent at 
older age (13). Several disorders seem to be related to migraine. For example, a 
higher prevalence of depression in patients with migraine has been demonstrated (14), 
and in a recently published case-control study an independent association between 
migraine and the risk of ischaemic stroke in young females was demonstrated (15). 
Furthermore, a temporal relationship between symptoms of migraine and the 
menstrual cycle, use of oral contraceptives, pregnancy and menopause has been 
described (16, 17). 
An association between cardiac events and migraine per se was first suggested by 
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Thomas and Post in 1925 (18). Since then, a number of case reports and case series 
has been published about the possible relationship between migraine and cardiac 
events (19-27). Furthermore, reports of patients in whom headache was a presentation 
of angina pectoris have been described (28-33). 
It has been shown that in patients with migraine, Raynaud's phenomenon is more 
frequent than in a nonmigrainous population (34). Furtllermore, an increased 
prevalence of migraine and Raynaud's phenomenon has been reported in patients with 
variant angina, and it has been suggested that migraine, Raynaud's phenomenon and 
variant angina are components of a generalized vasospastic disorder (35, 36). Also in 
a more recent study, an increased prevalence of migraine was found in patients with 
primary Raynaud's disease (37). In this study, chest pain was common in patients with 
primary Raynaud's phenomenon, in particular in those who had co-existing migraine. 
However, a small study failed to show signs of coronary vasospasm more frequently 
in patients with common attacks of migraine, when compared to patients with tension 
headache or to healthy individuals (38). Also another small study did not demonstrate 
a higher frequency of migraine 01' Raynaud's phenomenon in patients with variant 
angina (39). 
Serotonin has long been implicated in the pathophysiology of migraine (40). 
Furthermore, serotonin plays an important role in haemostasis and regulation of 
cerebral (41), coronary (42) and gastrointestinal (43) blood flows, and has been 
associated with a variety of diseases and disorders, such as cerebral (44) and coronary 
(45) vasospasm, Raynaud's phenomenon (46), thromboangiitis obliterans (Buerger's 
disease) (47), Carcinoid syndrome (48), pre-eclamptic hypertension (49), pulmonary 
arterial hypertension (50) and essential hypertension (51, 52). 
Within the past few years, several advances in the knowledge about vascular 
serotonin receptors have occurred (53). Firstly, it was observed that the diversity of 
serotonin receptors within one species is far greater than was previously thought. 
Secondly, substantial pharmacological variability may occur between species, 
indicating that studies in animals may be misleading, and cannot be extrapolated to 
humans. Thirdly, one specific serotonin receptor subtype within a particular species, 
may have different pharmacological effects, dependent on the specific characteristics 
of the SUbject. Endothelial dysfunction, for example, may lead to paradoxical effects 
on blood vessels. Fourthly, there are regional differences in the distribution of 
serotonin receptor SUbtypes, by example, relatively more 5-HT2 receptors in human 
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temporal arteries when compared to cerebral arteries (54). 
The local effects of serotonin on the blood vessels of the tissues in which it is 
formed and released, illustrate the duality of its vascular effects, causing either 
constriction or dilatation. In animals with coronary arteries without endothelial 
damage, serotonin causes a dose related biphasic response characterized by an initial 
increase in coronary-artery diameter followed by delayed vasoconstriction (55). It has 
been demonstrated that in beagle dogs, constriction of endothelium-denuded coronary 
arteries due to serotonin, is mediated by 5-HT\ -like receptors (56). 
In vitro studies demonstrated that serotonin constricts isolated human coronary-
artery rings (57). It has been shown that both 5-HT\-like and 5-HT, receptors mediate 
constriction of human epicardial coronary arteries (58), and that the effects mediated 
by 5-HT\-like receptors but not 5-HT, receptors are preserved in patients with 
ischaemic heart disease (59). Recently, it was reported that the relative contribution of 
5-HT\ like receptors in mediating constricting human epicardial coronary arteries 
predominate over 5-HT,-like receptors (60). In angiographic studies, serotonin has a 
vasodilating effect on normal coronary arteries (61). However, patients with coronary 
artery disease and patients with variant angina pectoris, do not have the normal 
vasodilator response to intracoronary serotonin, but rather exhibit progressive 
constriction (62). This phenomenon is comparable with the effects of acetylcholine on 
normal and diseased human coronary arteries (63). Possibly, the vascular responses to 
serotonin and acetylcholine are influenced by endothelial (dys-)function (64). Serotonin 
can stimulate release of the vasodilator nitric oxide (65) from endothelial cells (66), 
and it has been suggested that serotonin-induced vasodilation of peripheral arteries is 
mediated by nitric oxide (67). The vasodilation of coronary arteries after exposure to 
serotonin or acetylcholine may be mediated by the "nitric oxide (NO)-pathway", 
whereas the vasoconstriction may be an effect of direct stimulation of the smooth 
muscle cells in the arterial wall by serotonin or acetylcholine (figure 1). 
A coronary endothelial vasodilator dysfunction has been associated with factors like 
aging (68) hypertension and hypercholesterolemia (69) and smoking (70). However, 
further research is necessary to determine the associations between transmitters such 
as serotonin and acetylcholine, endothelial dysfunction and nitric oxide in causing 
cardiovascular disease (71). 
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Acetylcholine 
Serotonin 
Figure 1 M Possible effects of h"ansmitters slIch as serotonin and acetylcholine on 
arterial smooth muscle cell. Acetylcholine or serotonin are bound to receptors on an 
endothelial cell, resulting in release of nitric oxide to the smooth muscle cell in the 
arterial wall, which causes relaxation ('indirect' or 'normal' pathway). 
Acetylcholine and serotonin act directly on smooth lIIuscie cells oj the arterial wall 
(particularly in case oj endothelial dysjunction), and cause vasoconstriction ('direct' 
or 'diseased' pathway). 
Pharmacology and efficacy of slllnatriptan 
The pharmacodynamic and pharmacokinetic properties of sumatriptan have been 
reviewed previously (72, 73). In short, sumatriptan is a potent vascular 5-HT, agonist. 
Radioligand binding studies in animals demonstrated that sumatriptan has high affinity 
and relative specificity for 5-HT ID receptors, with minor affinity for 5-HT'A receptors. 
The chemical structure of sllmatriptan resembles serotonin (figure 2). Studies of 
animal and human isolated cerebral blood vessels showed a vasoconstrictor effect of 
sllmatriptan. 
At the recommended dose of 6 mg subcutaneously or 100 mg given orally, mean 
peak plasma concentrations (em",) of 72 "giL and 54 "giL sumatriptan were 
demonstrated after 10 minutes and 1.5 hours respectively. The bioavailability is over 
90 percent after subcutaneous administration, but only 14 percent after oral 
administration. The drug is transformed in the liver to an inactive indoleacetic acid 
metabolite that is excreted predominantly in the urine. The elimination half-life of 
sumatriptan is approximately two hours. The presence of a migraine attack does not 
affect the pharmacokinetic profile. 
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Figure 2 - Structural formulae of serotonin (5-hydroxy/lyptamine; 5-HT) and 
slImah'iplan. 
The major clinical trials in which the therapeutic effects of sumatriptan were studied, 
were conducted using a randomised, double blind, parallel group design, and 
included a placebo group (74). It was shown in these trials, that sumatriptan is 
effective in the treatment of acute attacks of migraine as well as cluster headache, 
and the use is widely advised (75). 
Trials in which sumatriptan is compared with active treatment, are less obvious. 
In a randomized double-blind comparison of sumatriptan and ergotamine, it was 
demonstrated that use of sumatriptan resulted in a more frequent reduction of 
migraine (66% vs 48%), but was also associated with a higher recurrence of 
migraine within 48 hours (76). In a recently published trial, in which sumatriptan 
was compared with both placebo and aspirin combined with metoclopramide, it was 
demonstrated that both the combination aspirin and metoclopramide and sumatriptan 
were more effectiver than placebo, bnt that aspirin + metoclopramide was as 
effective as sumatriptan (77). 
Adverse reactions attributed to sumatriptan 
According to the clinical trials, several adverse effects of sumatriptan occur early 
after its administration, but are Sh011 lasting and mild (78). Typical systemic 
symptoms are tingling, warm or hot feelings, nausea/vomiting, feelings of heaviness 
or pressure and flushing. A proportion of the adverse effects can be ascribed to 
migraine itself. A characteristic feature is the recurrence of headache within 24 hours 
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after administrating sumatriptan (79). The recurrence of headache after subcutaneous 
administration of sumatriptan can not be prevented bnt may be delayed by oral 
sumatriptan four hours after subcutaneous administration (80). After marketing of the 
drug, several patients were described who developed an increase in the frequency of 
migraine attacks with consequent dependence and misuse, after use of sumatriptan 
(81, 82). Preliminary results of a postmarketing study showed also misuse of 
sumatriptan by approximately 1% of the consumers (83). Two cases of hemiparesis 
have been repOlted, 12 hours and I week after subcutaneous administration of 
sumatriptan, respectively (84). However, according to the time-event relationship, a 
causal relation between use of sumatriptan and occurrence of the neurologic 
manifestations in these patients seems to be unlikely (85). The history of a 22-year-
old woman was described, who developed a stroke within minutes of a subcutaneous 
injection of sumatriptan (86). In retrospect, she had received sumatriptan for 
symptoms of a superior sagittal sinus thrombosis. 
Concern has been expressed about the safety in asthmatic patients with migraine 
(87). An analysis of the sumatriptan safety database of 75 clinical trials, however, 
showed no increase or change in the adverse reactions l'CpOlted to sumatriptan in 
asthmatic patients (88). 
Other adverse reactions to sumatriptan recently reported in literature, include 
ischemic optic neuropathy (89), depression (90) and skin sensitivity (91). There has 
been discussion about the safety of concomitant use of sumatriptan and selective 
serotonin reuptake inhibitors (92-94). 
Chest pain and cardiac adverse effects of stlmatl'iptan 
Shortly after marketing of sumatriptan, the case histories of some patients with 
typical attacks of angina pectoris were described (95). Moreover, patients with 
sumatriptan induced chest pain accompanied by electrocardiographic alterations were 
repolted in the United Kingdom (96), Denmark (97) and Sweden (98). Furthermore, 
cardiac arrhythmias attributed to sumatriptan were repOlted (99). Subsequently, 
myocardial infarction was reported in a middle-aged female without a history of 
cardiovascular disease (100). The reports published in literature are summarized in 
table I. 
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TABLE 1 Cardiac adverse reactions to sumatriptan as reported in literature" 
Reference 
Brown, et a1. (78) 
Willet, et a1. (%) 
Abrahamsen et aI. <YTJ 
SADRAC' ~S) 
Curtin, et aI. (99) 
" 
Age 
(years) 
? 
47 
61 
44 
42 
67 
Ottervanger, et aI.oOO) 47 
Lippolis et aI. (101) 38 
Boyd and Rohan'''''' 57 
Weidmann. et a1. (103) 49 
Walton, et 31(104) 46 
Kelly KM(105) 35 
O'Connor P, et ai' 43 
Gender Route of administration 
? intravenous 
male subcutaneous 
male subcutaneous 
female subcutaneous 
female subcutaneous 
male subcutaneous 
female subcutaneous 
female subcutaneous 
female ? 
female oral 
female subcutaneous 
female subcutaneous 
male oral 
# Only cardiac effects with electrocardiographic abnonnaIities 
• SADRAC = Sweden Adverse Drug Reaction Advisory Comntittee 
Cardiac abnonnaIity Comments 
angina pectoris ST -elevation on ECG 
angina pectoris ST -elevation on ECG 
angina pectoris ST depression on ECG 
angina pectoris T -negativety on ECG 
ventricular fibrillation within three minutes after first injection 
ventricular tachycardia history of ntitral valve surgery 
acute myocardial infarction previously healthy woman 
angina pectoris ST -elevation on ECG 
ventricular fibrillation patient died 
acute myocardial infarction coronary angiography normal 
angina pectoris 
cardiac arrest 
ST -elevation on ECG 
patient with occult coronary artery disease 
acute myocardial infarction minor irregularities in left coronary artery 
$ O'Connor P, Gladstone P. Oral sumatriptan-associated transmural myocardial infarction. Neurology 1995;45:2274-6. 
Although chest symptoms after use of sumatriptan were noted in several clinical 
studies (106, 107), it is surprising that in some studies, of which one with a study 
population of more than 600 patients, chest pain due to sumatriptan was not reported 
(9, 108, 109). Other authors estimated the frequency of the experience of sensations of 
pressure and tightness in the chest at 3 % to 5 % of patients treated with sumatl'iptan 
(78). The frequency of chest pain attributed to sumatriptan was lower in postmarketing 
studies based on reports from physicians (87, lIO, 111). An increasing incidence of 
chest symptoms with a higher dose of sumatriptan has been observed (112). During 
the early evaluation of sumatriptan, when it was administered intravenously, a case of 
possible myocardial ischemia was recorded: the patient experienced chest symptoms 
accompanied by ST-segment elevation on electrocardiography (78). 
There is some pharmacological evidence for myocardial ischaemia due to 
sumatriptan. Sumatriptan constricted isolated coronary arteries of beagle dogs (56). 
Human isolated basilar artery rings constricted in response to sumatriptan (113), as did 
normal and atherosclerotic human epicardial coronary artery rings from explanted 
hearts (58-60, 113-116). Furthermore, two small studies, in which patients undergoing 
diagnostic coronary arteriography were studied, demonstrated a significant reduction 
in coronary artery diameter after both intravenous and subcutaneous administration of 
sumatriptan (117, 118). It has been suggested that a-adrenoceptor-mediated 
vasoconstriction might be part of the mechanism of an increased response of coronary 
arteries to sumatriptan (119). Other authors suggested that coronary vasospasm after 
sumatriptan may be caused by (occult) endothelial dysfunction (120). According to the 
latter mechanism, the coronary effects of sumatriptan may be comparable to those of 
serotonin itself and acetylcholine (see figure I). The coronary vasoconstriction after 
sumatriptan may be more severe in the presence of thromboxane A, (121). Another 
explanation for sumatriptan-induced chest pain was recently reported (122): A small 
group of volunteers had abnormal oesophageal contractions after a supra therapeutic 
dose of sumatriptan. However, a previously reported case-history described a patient 
with sumatriptan associated chest pain without alterations of the pressure in the 
oesophagus following a sumatriptan injection (98). 
Differential diagnosis of chest pain 
It is of no doubt, that several patients experience chest pain or typical attacks of 
83 
angina pectoris after use of sumatriptan (87, 95, liD, 111). However, an important 
question is, whether or not this is a symptom of myocardial ischaemia. Classic angina 
pectoris was initially described by William Heberden in 1772 (123), whereas a variant 
form was described by Prinzmetal in 1959 (124). Angina pectoris is defined as a 
discomfort in the chest or adjacent areas, which is caused by myocardial ischemia and 
is associated with a disturbance of myocardial function but without myocardial 
necrosis (125). Because the discomfort of angina is not uniform, and other entities can 
mimic it, the differential diagnosis is often difficult. In general, no cardiac 
abnormalities can be identified in 10 - 30% of the patients with angina-like retrosternal 
chest pain (126), and oesophageal abnormalities can be found in 30-60% of these 
patients (127, 128). Another condition which causes pain that can resemble angina 
pectoris is a costosternal syndrome (129). Until now, there are only few studies in 
which sumatriptan related chest pain has been investigated, and it is still not clear 
what the cause of this chest pain in most patients is, and whether it is associated with 
cardiovascular risk factors. 
Conclusions 
Chest pain after use of sumatriptan seems to be a relatively common adverse reaction 
to this drug. As the reaction may also occur in young adults, it remains to be seen 
whether all such events can be solely explained by myocardial ischemia (130). On the 
other hand, since myocardial infarction due to sumatriptan has been demonstrated 
(100, 103), every case of chest pain after administration of sumatriptan, requires a 
careful evaluation, with respect to factors such as duration of chest pain, severity of 
the reaction and the presence of recognized cardiovascular risk factors. Sumatriptan is 
contraindicated in patients with ischaemic heart disease, (variant) angina pectoris or 
previous myocardial infarction. Because transient increases in blood pressure have 
been observed (78), the drug is also contraindicated in patients with uncontrolled 
hypertension. When these contraindications are taken into consideration and cases of 
chest pain are carefully evaluated, use of sumatriptan should not be the cause of 
unduly concern. Even so, however, postmarketing studies have to demonstrate which 
patients are at risk for developing chest symptoms and, in particular, cardiac adverse 
reactions. Another topic of interest concerns the exact mechanism of sumatriptan-
induced chest pain, especially in those instances in which myocardial ischemia has 
been excluded. 
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CHAPTER 7.1 
ADVERSE REACTIONS TO SUMATRIPTAN AS REPORTED BY 
DRUG DISPENSING GENERAL PRACTITIONERS 
Med Contact 1993;48: 169-71. 
BMJ 1993;307:1185. 
Introduction 
Many adverse drug reactions (ADR) are discovered within the first two years of 
marketing (1, 2), whereas most serious new ADR are detected by single case reports 
(3, 4). Single case reports and national voluntary reporting schemes give, however, no 
insight into the frequency or incidence of an ADR. 
In May 1991, the serotonin-I (5HT-I) agonist sumatriptan was registered in The 
Netherlands for the treatment of acute attacks of migraine and cluster headache. In 
clinical trials, sensations of pressure and tightness in the chest were experienced by 
3 % to 5 % of patients treated with sumatriptan, but no electrocardiographic (ECG) 
evidence of cardiac ischemia was demonstrated (5). In reports on postmarketing 
experience with sumatriptan, angina-pectoris-like pain was noted (6). In the literature, 
after subcutaneously administered sumatriptan, both chest pain, accompanied by ST 
elevation in the ECG (7), and an acute myocardial infarction in a previously healthy 
young female (8) have been reported. 
To get more insight into the incidence of cardiovascular adverse reactions due to 
sumatriptan in postmarketing experience, a study was performed in co-operation with 
general practitioners with a drug dispensing outlet. 
Patients and methods 
In July 1992, an enquiry was held among all 687 drug dispensing general practitioners 
in The Netherlands. These general practitioners are encompassing a catchment 
popUlation of approximately 1,500,000 inhabitants (10% of the total population in The 
Netherlands). They were asked to provide the date of birth and gender of every person 
to whom sumatriptan has been dispensed since it was marketed in May 1991. They 
were also asked about the route of administration and whether they had observed any 
adverse reaction in their patients. To avoid bias, in the questionnaire no adverse 
reactions were mentioned by name. The non-responders received two reminders, II 
and 17 weeks after the first request. Information was entered into a database and 
results were analyzed using two-tailed chi-square tests and t-tests. 
Resnlts 
The request yielded a response rate of 86% (589 general practitioners). Of these 589 
general practitioners, 474 had dispensed sumatriptan on at least one occasion to a total 
98 
of 1727 patients (24% males, 76% females). The general practitioners responded after 
an average of 26 working days (range 3 - 110 days). The mean age of the responding 
general practitioners was 47 years. There were no differences in age or gender 
between responding and non-responding general practitioners. Of the 589 GP, 477 
(81 %) were of the opinion that drug dispensing GP are suitable for this kind of 
postmarketing studies, since they have direct access to information on both dispensing 
drugs and disease data. 
Mean age of the 1727 patients was 43.8 years (SO 11.2). Of the 1662 patients 
(96 %) of whom information about the route of administration was available, 683 
patients (41 %) had taken sumatriptan orally, 842 patients (51 %) had administered 
sumatriptan subcutaneously and 137 patients (8%) had taken the drug by both routes. 
Of the 1727 patients, 185 patients (10.7 %, 95% CI 9.3% - 12.1 %) had reported one 
or more adverse reactions, which resulted in a total of 247 adverse reactions. Of these 
patients, 76 % was female. The mean age of the 185 patients was 43.3 years (SO 
11.2). The most frequent adverse reactions attributed to the use of sumatriptan were 
dizziness, nausea or vomiting, drowsiness or sedation, and chest pain, which were 
reported in 30, 26, 25 and 23 patients, respectively. Cardiovascular adverse reactions 
are summarized in table 1. 
TABLE 1 
Cardiovascular adverse reactions 10 sumatripfall ill 1727 
patiellts as reported by 474 gel/eral practitioners 
Adverse reaction No (%) 
Chest pain 23 (1.3) 
Palpitations 6 (0.35) 
Hypertension 2 (0.12) 
Syncope 2 (0.12) 
Bradycardia (0.06) 
Of one patient both chest pain and bradycardia was reported 
Chest pain was reported in 19 females and 4 males, of whom 8 patients had taken 
sumatriptan orally, 11 patients had administered sumatriptan subcutaneously and 4 
patients had taken the drug by both routes. Mean age of patients with chest pain was 
44.0 years (SO 6.4). The incidence of chest pain attributed to sumatriptan was 1.3 % 
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(95% CI 1.2% - 1.5%). Age, gender and route of administration in these patients did 
not differ from the other 1718 patients who received the drug (p > 0.05). 
Discussion 
Our postmarketing study yielded a high response rate of 86 % of the drug dispensing 
general practitioners, which is comparable to a study in 1990, in which a cohort of 
patients exposed to acitretine was traced by all Dutch drug dispensing outlets (hospital 
pharmacies, community pharmacies and drug dispensing GP) (9). 
There were three reasons for performing this study. Firstly, reports of angina 
pectoris and acute myocardial infarction forced us to estimate the incidence of chest 
pain under everyday conditions. Secondly, it is the intention to approach all patients 
who were treated with sumatriptan with a questionnaire to investigate whether non-
reported adverse reactions occurred as the incidence of chest pain in our study was 
lower than in clinical studies (5). However, in order to be recognized as an adverse 
reaction, patients have to visit their general practitioner and complain about their 
experiences. If patients fail to do so, the incidence of adverse reactions will be 
underestimated, in particular for reactions which are not severe. Finally, it is the 
intention to enrol patients with self-reported chest pain in a more detailed study to 
assess determinants of this adverse reaction. 
In the current study no serious adverse reactions, such as death, myocardial 
infarction or stroke, were reported. Drug dispensing general practitioners have direct 
access to data on drug dispensing and disease. Because of the excellent co-operation of 
drug-dispensing general practitioners, and their direct access to information on both 
dispensing drugs and disease data on an individual level, we conclude that this group 
of physicians provides a very useful resource for studying acute problems with adverse 
reactions to newly marketed drugs. 
An angiographic study suggested that sumatriptan may cause coronary artery 
vasoconstriction (10). The chest pain, as observed in 23 patients (1.3 %) in our study, 
and similar reports by others (6) highlight the need for an extensive study of this 
adverse reaction, especially as previous reports demonstrated both ECG abnormalities 
during chest pain due to sumatriptan (7) and myocardial infarction after chest pain due 
to sumatriptan (8). 
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CHAPTER 7.2 
ADVERSE REACTIONS TO SUMATRIPTAN AS REPORTED BY 
PATIENTS 
Bur J Clill Pharm 1994;47:305-9. 
Introductiou 
The serotonin-I (5HT-I) agonist sumatriptan is a new anti-migrainous dlUg, which 
was registered in several European countries and recently also in the United States (I). 
It has been demonstrated that use of sumatriptan is highly effective, rapid-acting and 
well-tolerated in the treatment of acute attacks of migraine (2). Migraine is a conmlon 
neurological disorder (3), that can severely affect quality of life and daily function. 
In May 1991 sumatriptan was registered in The Netherlands for the treatment of 
acute attacks of migraine and cluster headache. However, shortly after marketing of 
the dlUg, The Netherlands Centre for Monitoring of Adverse Reactions to DlUgS 
received several reports of typical attacks of angina pectoris after use of sumatriptan 
(4). The occurrence of these dlUg-related symptoms was confirmed by other 
investigators (5). Several reports from clinical trials did not mention chest symptoms 
after use of sumatriptan (2, 6, 7). Other authors estimated the frequency of the 
experience of sensations of pressure and tightness in the chest at 3 % to 5 % of patients 
treated with sumatriptan (8). Since no electrocardiographic (ECG) evidence of cardiac 
ischemia could be demonstrated in the clinical trials, the mechanism of these 
complaints remained unclear. However, after marketing of the drug, two patients were 
reported who developed chest pain, accompanied by serious ST abnormalities in the 
ECG, after sumatriptan 6 mg subcutaneously (9, 10), a young female developed an 
acute myocardial infarction after administration of subcutaneous sumatriptan (11), and 
two cases were reported of serious ventricular arrhythmias after use of this drug (12). 
Furthermore, two small angiographic studies demonstrated significant reduction of the 
coronary artery diameter in humans after both intravenous and subcutaneous 
administration of sumatriptan (13, 14). 
The postmarketing experience with sumatriptan forced us to perform a 
pharmacoepidemiological study, to get more insight into the incidence and the 
character of (cardiovascular) adverse reactions due to sumatriptan. 
Patients 
In July 1992, an enquiry was held among all 687 drug dispensing general practitioners 
in The Netherlands. They were asked to provide the date of birth and gender of every 
person to whom sumatriptan had been dispensed since it was marketed in May 1991. 
Subsequently, the general practitioners who had dispensed sumatriptan, were asked to 
send a questiollllaire to be completed at home, to the patients who had used 
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sumatriptan. The questionnaires were sent via the general practitioners in prestamped 
envelopes with a standard letter from our Centre. In the questionnaire, the patients 
were asked whether they had indeed used sumatriptan, and if so, whether they had 
observed possible adverse reactions after use of sumatriptan. Furthermore they were 
asked about the temporal relationship between administration of sumatriptan and the 
observed adverse reactions, and whether the possible adverse reactions recurred after 
rechallenge. Finally, they were asked whether they used other medication, and if so, 
what the indication was. To avoid bias, in the questiomlaire no adverse reactions were 
specified, and the general practitioners were not informed regarding our particular 
interest in chest pain. Chest pain was defined as pain or pressure feelings, located 
substernally or at the chest. The enquiry was sent to the patients in December 1992. 
The physicians of whom no patients had responded, received a reminder in March 
1993. Patients were classified as being diabetic if they used anti-diabetic dlUg therapy. 
Patients were considered as hypertensive if they were currently taking antihypertensive 
medication for tlle indication hypertension. ObstlUctive lung disease was assumed to 
be present if patients were using lung medication (mainly inllaled Jl-agonists and 
corticosteroids) for one or more of the indications astlmla, chronic bronchitis or 
emphysema. 
Data analysis 
Differences between group means were tested by Student's t test. A chi-square test 
was used to assess differences between proportions, with use of Fisher's exact test if 
there was an expected cell value of less than 5. 95 % Confidence intervals of 
proportions were calculated on the basis of an assumed binomial distribution (15). All 
calculated P values are two-tailed. Statistical significance was defined as a two-sided 
p-value of less than 0.05. Relative risks were calculated with 95% confidence intervals 
(95% Cl). 
Results 
The request to the 687 dlUg dispensing general practitioners yielded a response rate of 
86% (589 general practitioners). Of these 589 general practitioners, 474 had dispensed 
sumatriptan on at least one occasion to a total of 1727 patients (24% males, 76% fe-
males). During the study period, seven patients were lost to follow up, all by a change 
of residence. Of the 1720 remaining patients, 1202 (70%) returned the questiomlaire. 
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TABLE 1 
General characteristics of the study population 
Characteristic Patients (%) 
(number) 
Males 284 ( 24) 
Females 918 ( 76) 
Mean age (years) 43 ( 11 *) 
Obstructive lung disease 28 ( 2.4) 
Hypertension 49 ( 4.1) 
Diabetes Mellitus 4 ( 0.3) 
* Standard Deviation 
Basic characteristics of this study popUlation are summarized in table 1. It concerned 
284 males with a mean age of 44 years and 918 females with a mean age of 43 years. 
Fifteen patients (two males, thirteen females) had not yet used sumatriptan, and were 
excluded from further analyses. 
The most cOlmllonly suspected adverse reactions reported by the 1187 patients who 
had used sumatriptan, are shown in table 2. Most frequent were paraesthesia (139 
patients, 95% CI 9.9% - 13.5%) and dizziness (96 patients, 95% CI 6.5% - 9.7%). 
Chest pain after use of sumatriptan was reported by 94 patients (7.9 %, 95 % CI 6.4 % 
- 9.4 %) with a mean age of 41 years (not significantly different from the total study 
population), ranging from 19 to 69 years. This subgroup comprised 13 males (4.6%) 
and 81 females (9.0%), resulting in a relative risk of females compared to males of 
1.9 (95% CI 1.1 - 3.4). 81 of tllese patients (= 86%) experienced chest pain Witllin 
one hour after administration of sumatriptan, and in 83 patients (88%) the adverse 
reaction occurred more than once. Of the 94 patients who had experienced chest pain 
after use of sumatriptan, 6 patients (6.4%) had hypertension, a proportion that was not 
significantly different from the total study group. Dyspnea after use of sumatriptan 
was reported by 26 patients (2.2%, 95% CI 1.4% - 3.0%), 21 women and 5 men with 
an average age of 39 years. Of the 26 patients, 24 patients (92%) experienced dyspnea 
within one hour after administration of sumatriptan, whereas in 22 patients (85 %) the 
reaction recurred after rechallenge. Of the 28 patients with obstructive lung disease, 3 
patients experienced dyspnea after use of sumatriptan, as compared to 23 in the other 
patients, resulting in a relative risk of 5.4 (95% CI 1.7 - 16.9). 
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TABLE 2 
Frequency of the most commoll adverse reactions (frequency > 2 %) altributed to 
slimatriptan as reported by 1187 consllmers 
Adverse reaction Patients Frequency (%) 95 % confidence 
interval 
Abdominal pain 31 (2.6) 1.7 - 3.5 
Chest pain 94 (7.9) 6.4 - 9.4 
Dizziness 96 (8.1) 6.5 - 9.7 
Drowsiness/sedation 83 (7.0) 5.5 - 8.5 
Dyspnea 26 (2.2) 1.4 - 3.0 
Fatigue 54 (4.6) 3.4 - 5.8 
Feeling of heaviness 95 (8.0) 6.5 - 9.5 
Flushing 60 (5.1) 3.8 - 6.4 
Headache 37 (3.1) 2.1 - 4.1 
Injection site reaction 35 (3.0) 2.1 - 4.0 
Muscle pain 28 (2.4) 1.5- 3.3 
Nausea andlor vomiting 87 (7.3) 5.8 - 8.8 
Palpitations 33 (2.8) 1.9 - 3.7 
Paraesthesia 139 (11. 7) 9.9 - 13.5 
Pressure in throat 39 (3.3) 2.3 - 4.3 
Some patients reported more than one adverse reaction 
Discussion 
Postmarketing studies on adverse reactions to drugs can provide information not 
available fi'om premarketing studies, mainly because premarketing studies are 
necessarily limited in size and often exclude important subgroups of patients. One of 
the most worrying findings in our study was the high frequency of chest pain (7.9 %) 
after use of sumatriptan. According to both the close temporal relationship between 
intake of sumatriptan and chest pain, and the occurrence of the same symptoms after 
renewed exposure (positive rechallenge) in many patients, a causal relationship 
between use of sumatriptan and chest pain is probable in most of the patients. Another 
interesting adverse reaction is dyspnea, as reported by 26 patients (2.2 %). 
To investigate adverse drug reactions via dlUg dispensing general practitioners by 
sending a questionnaire via them to the consumers of a specific dlUg in their practices, 
is a unique and novel approach. By reason of stringent privacy lUles in The 
Netherlands (16), we sent the questionnaires not directly to the patients, but asked the 
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general practitioners to do so. The 687 general practitioners WiOl a drug dispensing 
outlet in The Netherlands encompass a catchment population of approximately 
1,500,000 inhabitants (10% of the total population in The Netherlands). For a 
physician-based study, 86 % cooperation is in fact remarkably high, compared to 
studies as by example in the United Kingdom (17), and offers the opportunity for 
future studies. The fact that the drug dispensing general practitioners register both 
morbidity and drug dispensing, makes them a very useful source of information for 
studying ad hoc problems with newly marketed drugs. Although the catchment 
population of the drug dispensing general practitioners may not be representative of 
the total population in every aspect, we think that it is regarding the determinants in 
our study. 
We did not include any reference group in our study for two reasons. Firstly, we 
were mainly interested in adverse reactions with a close temporal relationship with use 
of sumatriptan, and a relatively low background incidence in the middle-aged. As it is 
unlikely that many reference patients would have developed chest pain in the same 
short periods in which the index patients were exposed, a reference group was not 
deemed necessary. Secondly, as sumatriptan is contraindicated in patients with angina 
pectoris and variant angina, such patients might have been overrepresented in a 
reference group of patients with migraine. 
The assessment of the likelihood of a causal relationship between intake of 
sumatriptan and several reported reactions was difficult. Reactions such as nausea or 
headache could well have also been symptoms of the underlying disease, migraine or 
cluster headache. 
We have no direct data on the mechanism of the chest pain observed in our study 
group, but we can not exclude a cardiac origin. It is possible that in some patients the 
chest symptoms were caused by myocardial ischemia, due to sumatriptan induced 
coronary artery spasm. It is well known that coronary artery spasm can be induced by 
several drugs, including the antimigrainous drugs ergotamine and methysergide (18 -
20). Some evidence for this hypothesis with regard to sumatriptan can be found in the 
literature. Human isolated basilar artery rings constricted in response to sumatriptan 
(21), as did normal and atherosclerotic human epicardial coronary artery rings from 
explanted hearts (22, 23). Furthermore, two small studies, in which patients 
undergoing diagnostic coronary arteriography were studied, demonstrated a significant 
reduction in coronary artery diameter after both intravenous and subcutaneous 
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administration of sumatriptan (13, 14). Even during the early evaluation of 
sumatriptan, when it was administered intravenously, a case of possible myocardial 
ischemia was recorded: the patient experienced chest symptoms accompanied by ST-
segment elevation on electrocardiogram (8). After marketing, several case reports on 
cardiac disturbancies due to use of sumatriptan were published (9-12). However, 
despite these indications for a cardiac origin of the chest symptoms, we can not 
exclude an other mechanism. In general, no cardiac abnormalities can be identified in 
10 - 30% of the patients with angina-like retrosternal chest pain (24), and oesophageal 
abnormalities can be found in 30-60% of these patients (25, 26). 
The frequency of chest pain attributed to sumatriptan is remarkably high in our 
study. Although the response of 70% of the patients to the questiOIlllaire was high, the 
30 % of patients who did not respond to the questiOIlllaire might have influenced the 
results. However, even if the 516 non responding patients comprised not one single 
case of chest pain attributable to sumatriptan, the frequenoy would have exceeded 5 %. 
It is surprising that in several studies, of which one with a study group of more than 
600 patients, chest pain due to sumatriptan was not reported (2, 6, 7). Furthermore, 
the frequency of chest pain attributed to sumatriptan in our study is higher than in 
several clinical trials (27, 28), and in postmarketing studies based on reports from 
physicians (5, 29). In trials, a low incidence may be explained by rigorous patient 
selection with exclusion of patients with a history of angina pectoris and variant 
angina. Our postmarketing study in patients gave a much higher figure of chest pain 
than our study based on data from general practitioners (29). Apparently, cases of 
chest pain are easily missed unless the patient is specifically asked for adverse 
reactions. It cannot be excluded tllat in some patients in oUl' study, chest pain was 
induced by concomitant use of ergot alkaloids. 
It is not yet clear whether the effects of the serotonin-l agonist sumatriptan on 
coronary-artery dimensions differ between patients with and without coronary 
atherosclerosis. Serotonin itself has a vasodilating effect on normal human coronary 
arteries, but when the endothelium is damaged, as in coronary artery disease, 
serotonin has a direct, unopposed vasoconstricting effect (30), and in patients with 
variant angina it may cause occlusive coronary artery spasm (31). It has been 
suggested that in patients with ischaemic heart disease, constriction of coronary 
arteries are mediated in particular by 5-HT,-like receptors (32). Some clinical studies 
suggested a dose relationship with chest symptoms (33). Another reason why the 
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frequency of chest pain in our study was higher, may be the fact that the patients in 
our study had used sumatriptan on several occasions during the study period. 
However, our study gives no insight into the incidence pel' administration of 
sumatriptan. 
Dyspnea as an adverse reaction of sumatriptan has been previously reported (5), 
but the relationship with asthma has been disputed (34). We considered chronic use of 
lung medication for one or more of the indications asthma, chronic bronchitis or 
emphysema as a reliable marker of current obstl1lctive lung disease. An association of 
dyspnea attributed to sumatriptan with obstructive lung disease, was demonstrated in 
our study. The mechanism of this adverse reaction is unclear, but an increase of both 
the pulmonary arterial pressure and pulmonary wedge pressure due to sumatriptan has 
been demonstrated (13, 14). Furthermore, serotonin itself is a bronchoconstrictor, 
although this para-sympathetic effect is in particular mediated by stimulation of 5-HT, 
receptors (35). It is, however, not clear whether the dyspnea in our patients was due 
to pulmonary congestion, bronchospasm or anoUler mechanism. 
Based on the results of this study, and other postmarketing reports, we advise 
cautious use of sumatriptan, in particular in patients who experience chest pain after 
use of this drug. In our opinion, every patient with chest pain suggestive of angina 
pectoris, dl1lg-induced or not, requires a careful evaluation, including a history, 
physical examination, electrocardiogram, and simple laboratory tests (36). 
Furthermore, we recommend furUler investigations of the mechanism of the chest 
symptoms attributed to sumatriptan. It may be useful to assess risk factors for the 
development of chest pain due to sumatriptan. Finally, we conclude that sending a 
questionnaire to patients via their (drug dispensing) general practitioner is a very 
useful source of information for studying ad hoc problems with newly marketed drugs. 
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CHAPTER 7.3 
DIFFERENCES IN PERCEIVED AND PRESENTED ADVERSE 
REACTIONS TO DRUGS IN GENERAL PRACTICE 
submitted 
Introdnction 
D1UgS are increasingly used, and dl1lg use has become an economical factor of 
growing importance in health expenditure. In comparison with other therapeutic 
interventions, medications commonly are effective, cost-effective, and safe (I). 
However, although a new dl1lg is tested nowadays in a number of trials in the 
premarketing stage, its safety profile has not yet been fully elucidated at the time a 
drug is marketed. 
Spontaneous reporting schemes are considered good tools for the rapid 
identification of new and rare adverse reactions (2). Although single case-reports are 
frequently criticized as being not substantial enough to reveal a new dl1lg-safety 
problem, the usefulness of case reports has been demonstrated by Vemling, showing 
that most of the major adverse drug reactions were first described in case reports (3). 
However, spontaneous reporting has the disadvantage of selective reporting, false-
positive reporting and underreporting, and valid estimates of the frequency or 
incidence of an adverse reaction may not be obtained. 
An approach to determine the frequency of adverse reactions to a specific dl1lg is 
the Prescription Event Monitoring (PEM) scheme in the UK (4). A number of studies 
based on this system has been published (5-8). A potential limitation is that only 
medical events registered by the general practitioner (GP) can be studied with this 
approach. 
In a postmarketing cohort study on adverse reactions to sumatriptan, performed 
with assistance of drug dispensing GPs in The Netherlands, we compared the 
frequency of adverse reactions as reported by the GP with the adverse reactions 
reported by patients to this dl1lg. 
Methods & data analysis 
In May 1991, sumatriptan was registered in the Netherlands for the treatment of acute 
attacks of migraine and cluster headache. Approximately one year after registration, in 
July 1992, an enquiry was held among all 687 drug dispensing GPs in The 
Netherlands. They were asked to provide the date of birth and gender of every person 
to whom sumatriptan had been dispensed since it was marketed in May 1991. They 
were also asked about the route of administration and whether they had observed any 
adverse reaction in their patients. To avoid bias, no adverse reactions were specifically 
mentioned in the questionnaire. The non-responders received two reminders, 11 and 
114 
17 weeks after the first request. Subsequently, the GPs who had dispensed 
sumatriptan, were asked to send a questionnaire to be completed at home, to the 
patients who had used sumatriptan. The questiorUlaires were sent via the GPs in 
prestamped envelopes with a standard letter from our centre. In the questiormaire, the 
patients were asked whether they had indeed used sumatriptan, and if so, whether they 
had observed any adverse reaction after use of sumatriptan. Similarly, in this 
questionnaire, no adverse reactions were specifically mentioned. The enquiry was sent 
to the patients in December 1992. Physicians of whom no patients had responded, 
received a reminder 11 weeks after the first request. Several details of the study have 
been published previously (9, 10). 
Differences between group means were tested by Student's t test. A chi-square test 
was used to assess differences between proportions, with use of Fisher's exact test if 
there was an expected cell value of less tllan 5. 95 % Confidence intervals (95 % CI) of 
proportions were calculated on the basis of an assumed binomial distribution (11). All 
calculated P values are two-tailed, with statistical significance defined by a two-sided 
p-value less than 0.05. 
Results 
General characteristics of the study are summarized in the table. 
TABLE 
General characteristics of the study 
Characteristic 
Questionnaires to tile GPs 
Total GPs with drug-dispensing 
outlet in The NetllCrlands 
Responding GPs 
GPs who had dispensed 
sumatriptan 
Questionnaires to the patients 
Total patients using sumatriptan 
Lost to follow-up during study 
Responding patients 
Number (%) 
687 
589 (86) 
474 (80) 
1727 
7 
1202 (70) 
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The request to the drug dispensing GPs yielded a response rate of 86% (589 GP's). 
There was no difference in age or gender between responding and non-responding 
GPs. Of the 589 responding GPs, 474 had dispensed sumatriptan on at least one 
occasion to a total of 1727 patients (24% males, 76% females). The average number 
of patients per GP to whom sumatriptan had been dispensed was 3.9 (range 1 - 29, 
median 3). Of the 1727 patients, 185 patients (10.7 %, 95% CI 9.3% - 12.1%), of 
whom 76% was female, had reported one or more adverse reactions, which resulted in 
a total of 247 adverse reactions. The mean age of the 185 patients was 43.3 years (SD 
11.2). The most frequent adverse reactions attributed to the use of sumatriptan as 
reported by the GP's were dizziness in 30 (1.7%), nausea or vomiting in 26 (1.5%), 
drowsiness or sedation in 25 (1.4 %), and chest pain in 23 (1.3 %) patients. 
During the study period, seven patients were lost to follow up, all by a change of 
residence. Of the 1711 remaining patients, 1202 (70%) returned the questionnaire. 
The velocity of response of GPs and patients is depicted in figure 1. 
26 % of total res onse 
20 
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I 
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,/ '" 
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--- Response of GP 
W M _ _ _ _ Response of patients 
,--
---
6 8 10 12 14 
Weeks after mailing 
Figure 1 - VelocUy of response to the questionnaires. The patient questionnaires 
(- - - - - - ) were sent via their GP. 11 weeks after the ftrst questionnaires, a 
reminder lvas sent. 
Fifteen patients (two males, thirteen females) had not yet used sumatriptan, and were 
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excluded from futiher analyses. 905 patients (76%) repotied a good efficacy of 
sumatriptan, whereas 67 patients (5.6%) repotied no beneficial effect of sumatriptan 
on their complaints. Of the 654 patients (54%) who repotied an adverse reaction, 369 
(56%) observed the adverse reaction each time they administered sumatriptan. The 
most commonly suspected adverse reactions repotied by the 1187 patients who had 
used sumatriptan, were paraesthesia in 139 patients (95% CI 9.9% - 13.5%) and 
dizziness in 96 patients (95% CI 6.5% - 9.7%). Chest pain after use of sumatriptan 
was reported by 94 patients (7.9 %, 95% CI 6.4% - 9.4%). 
Neither the GPs nor the patients repotied serious adverse reactions such as death 
or hospital admission. A marked difference was present in frequency of adverse 
reactions as repotied by patients and as repotied by their GPs. Any adverse reaction 
was repotied by 654 patients (54%), while according to the GPs this occurred in only 
185 patients (11%, p < 0.001). Of the 185 patients on whom the GPs repotied an 
adverse reaction, 52 patients (28%) had more than one adverse reaction, whereas of 
the 654 patients 285 (44%) reported more than one adverse reaction (p < 0.001). 
Differences between the most commonly reported 
by GPs and patients are depicted in figure 2. 
adverse reactions to sumatriptan 
% of 
patients 
Dizziness Nausea Sedation 
Legend 
II General PfactitioneIs 
~ Patients 
Chest pain 
Figure 2 - Difforences in frequency oj the most common adverse drug reactions reported 
by general practitioners and by patients 
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Although it was not possible to link the results of the two questiotUlaires in each 
patient on an individual level, there was clearly a marked differential repOliing 
between patients and OP's. Of the 30 patients on whom the OP reported dizziness, 
two patients rep0l1ed paraesthesia and two other patients repOlied flushing. Of the 26 
patients with, according to their OP, vomiting/nausea after use of sumatriptan, three 
patients reported chest pain, one patient dysphagia, and three patients dizziness. Of 
the 23 patients with, according to their OP, chest pain after use of sumatriptan, one 
patient reported hypertension, one dyspnoea and one palpitation. 
Discussion 
To investigate adverse drug reactions via drug dispensing OPs by sending 
questionnaires both to the OPs and to their patients using a specific drug, is a novel 
approach. In the Netherlands, one of the specific tasks of general practice is the role 
of gatekeeper (12), observing both complaints which do not require entry to 
secondary care services and complaints which are inUllediately presented to 
secondary services. The 687 OPs with a drug dispensing outlet in The Netherlands 
encompass a catchment population of approximately 1,500,000 inhabitants (10% of 
the total population in the Netherlands). Because they register both morbidity and 
drug dispensing, they are a useful source of information for studying ad hoe 
problems with newly marketed drugs. The fact that the patients were a little slower 
in responding to the questiOlUlaires than the OPs, can be explained by the fact that 
mailing of questiOlUlaires via their OP introduced an additional time delay. 
Although drug dispensing OPs are mainly located in rural areas without a 
community pharmacist, different from the U.S. (13) in the Netherlands only 
moderate differences exist between cities and these rural areas regarding population 
parameters, disease fi'equencies and health care coverages. 
One explanation for a difference in the reported ADRs by patients and by their 
OPs may be that for logistic reasons there was a few months time period between 
mailing the two questionnaires. We first had to know how many patients on 
sumatriptan each OP had, in order to send the OP the appropriate number of 
pres tamped envelopes with questionnaires. Because of stringent privacy rules in The 
Netherlands (14), we sent the questionnaires not directly to the patients, but asked 
the OPs to do so. Still it seems unlikely that the somewhat longer use of sumatriptan 
explains the so much higher number of patients with adverse reactions, as at least 
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56% of the patients repOlted that they observed the adverse reaction each time they 
used sumatriptan, or repOlted an adverse reaction already at first intake. FUlthermore, 
in our study, more frequent use of sumatriptan was not associated with a higher 
Jl'equency of reported adverse reactions. 
Another reason for the differences between repOlting by GPs and patients may be 
that only non-serious adverse reactions were repolted in this study. For an adverse 
reaction to be detected by their GP, patients have to visit the GP and complain about 
their experiences. If patients do not do so, the incidence of adverse reactions will be 
underestimated in postmarketing studies based on repOlts of GPs, in patticular when 
they are not severe, albeit that reactions, sometimes considered as non-serious by 
patients (such as chest pain by sumatriptan) Catl result in serious, life-threatening 
situations (15). 
The metaphor 'iceberg of morbidity' is used for presented morbidity as a fraction 
of the total morbidity (16). Knowledge of the magnitude of this 'iceberg' is 
important. It has been suggested that approximately 10% of all experienced 
complaints are repOlted to the GP (17, 18). In our study, any adverse reactions was 
repOlted by 54% of the patients, whereas the GP's had registered it on 11 % of the 
patients, suggesting a sensitivity of approximately 20%. So it seems to be, that 
adverse dmg reactions might be more readily presented to the GPs or registered by 
the GPs than health complaints in general. 
To detect the frequency of complaints of patients by review of medical records of 
GPs, it is not only necessary that the patients consult their GP, but also that the GP 
records it in the medical file. For example, it has been demonstrated that review of 
the medical record about advice on smoking and alcohol given by the GP, will lead 
to significant underestimation of the frequency of advice given, as many advices are 
not recorded (19). 
Although the response to the questionnaire by 70% of the patients was high, the 
non-response by 30% of the patients could have influenced the results. However, 
even if none of these patients observed an adverse reaction, the frequency of repOlted 
adverse reactions by the patients is still significantly higher than the frequency 
reported by their GPs. 
Prescription-event monitoring (PEM) was developed in 1980 by the Dmg Safety 
Research Unit (DSRU) in the UK, as a novel national approach for detecting adverse 
events occuning during dmg treatment (4). In PEM the patient, dmg and doctor are 
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identified from the prescriptions gathered by the Prescription Pricing Authority 
(PPA). Thereafter, simple questionnaires (green forms) are sent to the prescribing 
doctors 6 to 12 months after the prescription has been written, asking for all 'events' 
that happened since the prescription and some additional information, such as age 
and diagnosis. And although the majority of reported events are in fact no adverse 
dmg reactions (but rather related to the disease being treated or co-incidental), it 
appears to be a usen!! approach. However, oU!' study shows that the frequency of 
adverse reactions may be considerably underestimated if only GP records are used. 
An example of this phenomenon in PEM was the estimated frequency of cough with 
enalapril (20, 21) as discussed by Waller (22). 
Because of the excellent co-operation of dmg-dispensing GPs, their direct access 
to information on both dispensing dl1lgs and disease data on an individual level, and 
the possibility to contact patients using a specific dl1lg directly via them, we 
conclude that this group of physicians provides an impOltant resource for studying 
acute problems with adverse reactions to newly marketed dl1lgs. Patients experience 
adverse reactions significantly more fi'equently than are observed by their GPs, and 
postmarketing studies based on data from GPs, may result in a considerable 
underestimation of the cumulative incidence of adverse reactions. 
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CHAPTER 8 
DETERMINANTS OF OVERUSE OF SUMATRIPTAN 
Eur J Clio Pharmacol 1996 (in press) 
Introduction 
The serotonin-l agonist sumatriptan is a relatively new drug used in the treatment of 
acute attacks of migraine and cluster headache (1). Adverse drug reactions attributed 
to sumatriptan in the postmarketing period include acute myocardial infarction (2, 3), 
depression (4), and skin reactions (5). 
A characteristic feature is the recurrence of headache within 24 hours after 
administrating sumatriptan (6). After marketing of the drug, several patients were 
observed who developed an increase in the frequency of migraine attacks with 
consequent dependence and misuse, after use of sumatriptan (7-9). Preliminary 
results of a postmarketing study based on pharmacy records also showed overuse of 
sumatriptan by approximately 1 % of the consumers (10). 
We investigated the frequency of use and ovelUse of sumatriptan in a postmarketing 
cohort study, and explored characteristics of patients repmting overuse. 
Methods and data analysis 
In May 1991, sumatriptan was registered in the Netherlands for the treatment of 
acute attacks of migraine and cluster headache. In July 1992, an enquiry was held 
among all 687 dlUg dispensing General Practitioners (GP) in The Netherlands, to 
provide the date of bitth and gender of every person to whom they had dispensed 
sumatriptan since marketing. Subsequently, they were asked to send a questionnaire 
to be completed at home, to the patients who had used sumatriptau. The 
questionnaires were sent via the GP in prestamped envelopes with a standard letter 
from our centre. In the questionnaire, the patieuts were asked whether they had 
indeed used sumatriptan, and if so, how often sumatriptan was used, what the 
efficacy of sumatriptan was and whether they had observed any adverse reaction 
after use of sumatriptan. In the questionnaire, no adverse reactions were mentioned 
by name. Some details of the study have separately been published previously (11, 
12). 
Use of sumatriptan was classified into five groups: < 1, 1-10, 11-20 and 21-30 
administrations per month, and a fifth group of patients who repmted daily 
sumatriptan use or more than 10 administrations each week. Patients in the latter 
group were regarded as 'over-users'. 
Differences between group means were tested by Student's t test. A chi-square 
test was used to assess differences between propmiions, with use of Fisher's exact 
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test if there was an expected cell value of less than 5. All calculated P values are 
two-tailed. Statistical significance was defined as a two-sided p-value of less than 
0.05. Relative risks (RR) were calculated with 95% confidence intervals (95% el). 
Results 
Of the 589 Dutch general practitioners (86%) who participated in this study, 474 had 
dispensed sumatriptan on at least one occasion to a total of 1727 patients (24% 
males, 76% females). During the study period, seven patients were lost to follow up, 
all by a change of residence. Of the 1720 remaining patients, 1202 (70%) returned 
the questionnaire. Of 952 (79%) of these patients full details of their sumatriptan 
intake were available. 
General characteristics of the study population are summarized in table I. 
TABLE 1 
General characteristics of 952 patients with information on slimatriplan consumption 
Characteristic 
Age (years) 
Males 
Reported efficacy of sumatriptan 
Good 
Moderate 
Poor 
Not reported 
Route of administration 
Oral 
Subcutaneous 
Both routes 
Missing 
Average duration of 
headache complaints (years) 
Any adverse reaction 
Headache after slimatriptan 
SD ~ Standard Deviation 
Number OJ' mean 
44 (SD: II) 
224 (24%) 
729 (77%) 
77 (8%) 
55 (6%) 
91 (9%) 
318 (33%) 
458 (48%) 
82 (9%) 
94 (10%) 
21 (SD: 13) 
529 (56%) 
34 (4%) 
A total of 34 patients (4%) reported (rebound) headache due to use of sumatriptan, 6 
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males and 28 females (gender distribution not significantly different fi'om the other 
patients). In figure I the consumption of sumatriptan is depicted. 
Ntlml)}1J: of consumers 
< I I - 10 11 - 20 
Legend 
II Number (left axis) 
fill % (dght axis 
21 - 30 
Administration of "umatri tan er month 
% 
20 
10 
Figure 1 - Consumption of slimatriptan in 952 patients of drug dispensing general 
practitioners. Consumption was classified into jive groups: < 1, 1-10, 11-20 and 21-30 
administrations per month and a highest group of patients who reported daily use 
sumatriptan 01' more than 10 adminish'ations each week. 
Most patients (718, 75%) consumed sumatriptan 1-10 times each month. 36 patients 
(4%, 95% CI 2.8%-5.2%) used sumatriptan daily or more than 10 times each week, 
and were regarded as 'over-users', of whom 17 patients used sumatriptan once every 
day, 14 patients took sumatriptan two times each day, 3 patients three times each 
day, and 2 patients rep0l1ed that they used sumatriptan more than 10 times each 
week (not specified per day). Of the 36 patients, 13 (36%) were males, which was 
more than in the patients who used less than 10 consumptions of sumatriptan per 
month (192 males, relative risk 1.9, 95% CI 1.0-3.7). There were neither differences 
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in age, duration of headache complaints nor in route of administration between the 
five groups of intake. Of the 36 patients who took sumatriptan daily or more than 10 
times each week, 6 patients reported the efficacy of sumatriptan as poor, compared 
to 49 patients of the 916 patients who used sumatriptan less than 30 times each 
month (RR~3.3 95% CI 1.4-7.5). One or more adverse reactions were repOlied by 18 
patients (50%) of the over-users, compared to 511 patients (56%) of the others 
(p~0.5). Headache as an adverse reaction to sumatriptan was repOlied by 1 'over-
useI" (2.8%), compared to 33 patients in the other groups (3.6%; not significantly 
different). 
Discllssion 
We found that a small proportion (4%) of the consumers used sumatriptan daily or 
more than 10 times each week. Since sumatriptan is a drug for acute attacks of 
migraine or cluster headache, and not for prophylactic use, we regarded this group as 
'over-users'. It has previously been recOlmnended that patients with headaches 
should never take analgesics every day, and that ergotamine should not be taken 
more than 10 times a month (13). Oveluse was in our study significantly more 
frequently observed in males, and in patients who repOlied the efficacy of 
sumatriptan as poor. 
Analyses of medication consumption based on dispensing or reimbursement data 
have two major limitations: 1) no information is available on non-compliance; and 2) 
no information is available on drugs which are bought 'over the counter'. 
FUlihermore, these pharmacy records based studies do not provide direct information 
on efficacy, clinical events or adverse drug reactions observed by consumers. In our 
postmarketing study we used information on drug-use obtained directly from 
consumers. Because of strict privacy rules in The Netherlands, we could not validate 
these data by evaluating the records of the drug dispensing general practitioners, We 
think, however, that these data give good insight into the consumption of sumatriptan 
in these patients, although negative misclassification may exist. 
Several explanations for over-use may be considered. The most impOliant reason 
for more frequent use of sumatriptan is possibly a higher attack rate of migraine or 
cluster headache, but information on attack rates was not available in our study. 
However, it was demonstrated in our study that an observed low efficacy of 
sumatriptan accompanied more frequent over-use. Previously, headache recurrence 
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after sumatriptan use was repotied (14-16). It has been suggested that the rebound 
headache may be the underlying mechanism of over-use of sumatriptan (10, 15). 
However, the (rebound) headache was not associated with over-use in our study. 
Another explanation, more compatible with OUl' data, is that some patients use 
sumalriplan in too low a dose or Ihal in some patients the activity of sumatriptan is 
too shoti. 
In conclusion, we found that 4% of patients consuming sumalriptan, used this 
drug daily or more than 10 times per week. Over-use was associated with a repolied 
poor efficacy of sumatriptan and with male gender, but not with (rebound) headache 
after sumatriptan. Drug consumption patterns of sumatriptan have to be evaluated in 
all patients, but in patiicular in patients who report low efficacy of sumatriptan. 
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CHAPTER 9 
CHARACTERISTICS AND DETERMINANTS OF 
SUMATRIPTAN ASSOCIATED CHEST PAIN 
Submitted 
Introduction 
The serotonin-l (5HT -1) agonist sumatriptan is a relatively new anti-migrainous dlUg 
(1, 2). There are observations suggesting that sumatriptan also has cardiac side effects 
(3). Both intravenous and subcutaneous administration of sumatriptan result in a 
significant reduction in coronary artery diameter (4, 5), an effect which can be 
reversed by administration of glyceryl trinitrate (6). Furthermore, several case reports 
have been published in the medical literature concerning myocardial ischaemia and 
myocardial infarction, after administration of sumatriptan (3, 7-11). 
Chest pain associated with intake of sumatriptan has been estimated to occur in up 
to 8% of patients treated with sumatriptan (12-16). To investigate chest pain attributed 
to sumatriptan in more detail, we performed a postmarketing cohort study. Primary 
aims of the study were to identify characteristics and independent determinants of 
chest pain in relation to sumatriptan use. 
Patients and methods 
Selling 
In The Netherlands, a cohort study on adverse reactions to sumatriptan was performed 
with assistance of drug dispensing general practitioners (GPs), as described in detail 
previously (13, 16). In short, with assistance of 589 dlUg dispensing GPs in The 
Netherlands (86%), 1727 patients who had received sumatriptan were traced in July, 
1992. Via their GP, a questionnaire about use of sumatriptan, adverse reactions and 
use of other medication was sent to these patients in December 1992. To avoid bias, 
in the questionnaire no adverse reactions were specified, and the GPs were not 
informed regarding the particular interest in chest pain. During the study period, seven 
patients were lost to follow-up. Of the 1720 remaining patients, 1202 (70%) responded 
to the questionnaire, of which 1187 had indeed used sumatriptan. Chest pain, defined 
as pain or pressure feelings, located substernally or at the chest, was reported by 94 
patients (7.9 %, 95% CI 6.4% - 9.4%), and according to the close temporal 
relationship with intake of sumatriptan and the reported positive rechallenge in many, 
a causal relationship was probable in these patients. These 94 patients were traced 
from 91 GPs. The cohort for the present study consisted of all patients from these 91 
GPs who had ever used sumatriptan in the study period. 
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Patients 
The study protocol was approved by the Medical Ethics Committee of the University 
Hospital 'Dijkzigt' Rotterdam (MEC 140.112/1994/168), and written informed consent 
was obtained from all patients (n=347, 95%) who were visited at home. 
Patients were eligible for the study if they were consumers of sumatriptan who 
reported sumatriptan associated chest pain in the questiollllaires. Patients who reported 
chest pain both at the "open question" in the first questiollllaire, and at a specific 
question in a second questiollllaire which had been sent several weeks later were 
classified as patients with "probable" sumatriptan-induced chest pain. Patients who had 
not reported sumatriptan associated chest pain at the "open question" but only at the 
specific question, were classified as patients with "possible" sumatriptan-induced chest 
pain. Location of the pain or pressure sensations in association with intake of 
sumatriptan, had to be at the sternum, left thoracic wall or left shoulder. Chest pain 
had to occur within 6 hours after administration of sumatriptan. Determinants of 
probable and possible chest pain were analyzed both together and separately. A 
reference group was formed by consumers of sumatriptan with the same GP as the 
case, who reported neither at the open question nor at the specific question any type of 
chest pain or pressure after use of sumatriptan. The total study population consisted of 
420 patients on sumatriptan, from 91 drug dispensing GPs. 
Data collection and measurements 
All subjects received a (second) detailed questiollllaire. Non-responders received a 
reminder after three weeks. Furthermore, the study population was visited at home by 
the first author for a specific interview with regard to type of headache, presence of 
angina pectoris and Raynaud's phenomenon. The visit at home also included a 
physical examination and collection of blood samples. Physical examination consisted 
of measurements of length and weight, pulse, blood pressure and peak expiratory 
flow. All patients who were visited gave written informed consent. Finally, 
information from the GP was requested about the medical and drug dispensing history 
of the patients. The drug dispensing history was studied over the period between May 
1991 (introduction of sumatriptan in The Netherlands) and January 1995. 
Blood pressure measurements were made in the sitting position using an automated 
digital device, type Omron HEM403C (17). The heart rate was read from the digital 
display of the blood pressure device. Peak expiratory flow was measured with a mini 
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flow meter. All patients were instmcted to inhale maximally and exhale maximally, 
not using a nose clip. They repeated this procedure three times, and the highest 
measurement was recorded. 
Migraine was defined according to the criteria of the International Headache 
Society Headache Classification Committee for migraine. Angina pectoris was defined 
according to the Rose questionnaire (18). 
Hypertension was defined as a systolic blood pressure of at least 160 nnn Hg 
and/or a diastolic blood pressure of at least 95 mm Hg, or current use of 
antihypertensive medication for hypertension. The presence of Raynaud's phenomenon 
was considered if patients had complaints of biphasic discolorations of the digits 
during cold, accompanied by feeling numb (19). 
Data analysis 
Differences between group means were tested by Student's t test or with the Mann-
Whitney test in case of non-normal distribution. A chi-square test was used to assess 
differences between proportions, with use of Fisher's exact test if there was an 
expected cell value of less than 5. All calculated P values are two-tailed. Statistical 
significance was defined as a two-sided p-value of less than 0.05. To adjust for 
possible confounders, multivariate analysis was performed, by fitting a logistic 
regression model, permitting calculation of odds ratios which may be interpreted as 
relative risks (RR), and 95 % confidence intervals. Age (continuous variable) and 
gender and all variables which were significantly different between patients with and 
without chest pain attributed to sumatriptan, were included in the final multivariate 
model. 
Stratified analyses were performed in males and females, and in patients with 
probable and possible sumatriptan-induced chest pain. 
Resnlts 
The current study was based on 420 users of sumatriptan, who were all patients of 91 
drug dispensing GPs who had at least one patient with chest pain to sumatriptan. Of 
these 420 patients, 372 (89%) responded to the second, detailed questionnaire. Six 
patients (1.6%) had not yet used sumatriptan, and were excluded from the study 
population. Of the 366 remaining patients, 347 (95%) were visited at home. Of 16 
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patients (5 %) no blood sample was collected because the patient refused or because it 
was not possible to collect a sample for other reasons. 
A total of 130 patients with chest pain attributed to sumatriptan and 217 patients on 
sumatriptan without chest pain were examined. General characteristics of the study 
population are summarized in table 1. 
TABLE 1 
General characteristics of the study population (N ~ 366) 
Characteristic Number or mean (% or SD) 
Females 293 (80) 
Age (years) 43.9 (IO.2) 
Indication for sumatriptan: 
- Migraine 194 (53) 
- Cluster headache 13 ( 4) 
- Tension headache 6 ( 2) 
- Combination of headaches 142 (39) 
- Not stated 11 (3) 
Administration of sumatriptan: 
- Subcutaneous 170 (46) 
- Oral 93 (25) 
- Both subcutaneous and oral 101 (28) 
Systolic blood pressure (nml Hg) 129 (16.8) 
Diastolic blood pressure (mm Hg) 82 (12.0) 
Cholesterol (mmolll) 6.0 (1.1) 
- HDL (mmolll) 1.7 (1.1) 
- LDL (mmolll) 4.0 (1.1) 
Peak expiratory flow (l/min) 389 (81) 
Body mass index (kg/m') 23.5 (2.9) 
Current smokers 97 (27) 
Raynaud's phenomenon 40 (II) 
Angina pectoris 21 ( 6) 
History of myocardial infarction 3 ( I) 
SD ~ Standard deviation 
The mean age of the 137 patients with chest pain after use of sumatriptan (mean age 
42 years, SE 0.86) was significantly different from patients without chest pain after 
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use of sumatriptan (45 years, SE 0.68 p<0.05). Other general characteristics dit not 
differ between the two outcome groups. During the follow-up period of approximately 
two years, 82 patients (22 %) discontinued use of sumatriptan. Patients with chest pain 
to sumatriptan discontinued use more often (34% vs. 16%, relative risk (RR) 2.7 95% 
confidence interval (CI) 1.6 - 4.6). 
A positive rechallenge (renewed occurrence of chest pain after renewed exposure to 
sumatriptan) was reported by 113 patients (80 %) with sumatriptan-associated chest 
pain. Chest pain occurred within 30 minutes after administration of sumatriptan in 10 I 
patients (74%), between 30 minutes and 2 hours after administration in 48 patients 
(35%) and between 2 and 6 hours after administration in 9 patients (7%). The duration 
of sumatriptan-associated chest pain was less than 30 minutes in 78 patients (57%), 
between 30 minutes and one hour in 35 patients (26%), between I and 2 hours in 18 
patients (13%) and longer than 2 hours or not specified in 6 patients (4%). Differences 
in time relationship and duration of chest pain between oral and subcutaneous 
administration are shown in table 2. 
TABLE 2 
Differences ;,/ time relationship and duration of chest pain between oral and subcutaneous administration 
of sumatripfan, in 137 patients with chest pain after use of sumatriptan 
Oral administration 
N (%) 
Temporal relatiollsh;p between administration and c/tes/ pain * 
Within 30 minutes 18 (31) 
30 minutes - 2 hours 34 (59) 
2 - 6 hours 6 (10) 
Total patients in colunm 58 
Duration of suma/riptan-associated chest pail1$ 
Less than 30 minutes 
30 minutes - 1 hour 
1 hour - 2 hours 
Longer than 2 hours or not specified 
Total patients in colunm 
13 (35) 
14 (38) 
8 (22) 
2 (5) 
37 
Subcutaneous administratio 
N (%) 
83 (83) 
14 (14) 
3 (3) (p < 0.00 
100 
56 (71) 
12 (15) 
8 (10) 
3 (4) (FO.003) 
79 
N = number of patients with the characteristic; % = percentage of patients in each column. 
* 21 patients had chest pain after both the oral and subcutaneous administration of sumatriptan. 
$ Only patients (116) with either chest pain only after subcutaneous or only after oral administration 
of sumatriptan. 
All variables collected were compared between patients with and without chest pain 
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after use of sumatriptan. No differences were found in body mass index, peak 
expiratory flow, smoking, history of myocardial infarction, cln'onic obstructive lung 
disease, use of oral contraceptives, use of coffee or tea, concomitant use of ergot 
alkaloids, serum cholesterol level (including HDL and LDL fractions), or family 
history of migraine or sudden death. There was, however, a statistically Significant 
difference in blood pressure, the frequency of gastrointestinal complaints, and of a 
family history of myocardial infarction. The mean systolic blood pressure in patients 
with chest pain after use of sumatriptan was 132 mm Hg (SE 1.5) and 127 mm Hg 
(SE 1.1) in controls (p<0.005). Diastolic blood pressure was 84 nun Hg (SE 1.1) in 
patients with chest pain and 81 mm Hg (SE 0.7) in the other group (table 3). 
TABLE 3 
Comparisoll between paOents wit" chest pain attributed to sumatriptan and patients WWlOlit chest pain 
after intake of sumatriplan 
Characteristic Patients with chest uain Patients WitllOut chest gain Odds ratio (95 %-
Number Of mean (% or SE) Number or mean (% or SE) confidence interval) 
Number 137 229 
Age (years) 42 (0.86) 45 (0.68) 0.98 (0.96 - 0.99) 
Females 115 (84) 179 (78) 1.5 (0.8 - 2.6) 
Males 22 (16) 50 (22) 
Route of administration: 
Oral* 34 (25) 60 (26) 0.9 ( 0.6 - 1.6) 
- Subcutaneous , 64 (47) 106 (46) 1.0 (0.7 - 1.6) 
- Both+ 39 (28) 62 (27) 1.1 (0.7 - 1.8) 
Gastrointestinal complaints: 
- Dyspepsia 89 (65) 111(48) 2.0 (1.3 - 3.1) 
Raynaud's phenomenon 23 (17) 17 (7) 2.5 (1.2 - 5.2) 
Angina Pectoris 13 (9) 8 (4) 2.9 (1.1 - 7.9) 
AMI 1 (1) 2 (1) 
Blood pressure: 
Systolic (mm Hg) 132 (1.5) 127 (1.1) 1.02 (1.0 - 1.03) 
- Diastolic (mOl Hg) 84 (1.1) 81 (0.7) 1.02 (1.0 - 1.04) 
- Hypertension 34 (25) 30 (13) 2.2 (1.2 - 3.9) 
Family history 
of migraine 89 (65) 147 (64) 1.0 (0.7 - 1.7) 
- of AMI < 65 years 37 (27) 33 (14) 2.2 (1.3 - 3.9) 
SE ~ Standard Error 
* compared to patients with another kind of adrninistration(s) 
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As chest pain on a cardiovascular basis may show gender differences, a separate 
analysis was performed in males and females. Here, there was a moderate difference 
in total serum cholesterol and LDL fraction in males: Mean total cholesterol in males 
with chest pain after sumatriptan was 6.3 01010111, with LDL-cholesterol 4.6 mmoll1, 
whereas in males without chest pain after sumatriptan total serum cholesterol was 5.9 
01010111 (p=0.2), with LDL-cholesterol 4.0 01010111 (p=0.06). Hypertension and a 
family history of myocardial infarction were strong predictors of sumatriptan-induced 
chest pain in males, relative risk 8.0 (95% CI 1.8-40) and 5.9 (95% CI 1.1-39.4) 
respectively. 
Age (continuous variable) and gender and all variables which were significantly 
different between patients with and without chest pain, were included in the final 
multivariate model. The results of the multivariate analysis are given in table 4. 
TABLE 4 
Multivariate analysis of risk jactors of smnalr/ptan associated chest pabl, all patients alld 
stratified by gender 
Characteristic 
All patiellts 
Females 
Age (per year) 
Dyspepsia 
Raynaud's phenomenon 
Hypertension 
Family history of AMI 
Angina pectoris 
Females 
Age (per year) 
Dyspepsia 
Raynaud's phenomenon 
Hypertension 
Family history of AMI 
Angina pectoris 
Males 
Age (per year) 
Dyspepsia 
Raynaud's phenomenon 
Hypertension 
Family history of AMI 
Angina pectoris 
AMI = Acute Myocardial Infarction 
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Relative Risk 
1.5 
0.97 
1.9 
2.1 
2.2 
1.4 
2.4 
0.97 
2.0 
2.4 
1.6 
1.3 
2.1 
0.95 
1.7 
0.7 
9.8 
7.7 
1.7 
95 % Confidence interval 
0.8 - 2.7 
0.94 - 0.99 
1.2 - 3.0 
1.0 - 2.9 
1.2 - 4.0 
1.0 - 1.8 
0.9 - 6.4 
0.94 - 0.99 
1.2 - 3.3 
1.1 - 5.0 
0.8 - 3.0 
0.97 - 1.7 
0.7 - 6.2 
0.9 - 1.0 
0.9 - 6.3 
0.04-10.7 
2.1 - 45.1 
1.4 - 43.9 
0.1 - 25.3 
Raynaud's phenomenon was a significant risk factor for sumatriptan-associated chest 
pain in females (relative risk 2.4; 95% CI 1.1-5.0) but not in males, whereas in males 
in particular hypertension (RR 9.8; 95% CI 2.1-45) and a family history of acute 
myocardial infarction (RR 7.7; 95% CI 1.4-43.9) were associated with sumatriptan-
associated chest pain. When angina pectoris was excluded from the multivariate 
model, the risk of hypertensive males on sumatriptan-induced chest pain increased. 
There were 93 patients with probable sumatriptan-induced chest pain and 44 
patients with possible sumatriptan-indllced chest pain. Separate analyses of risk factors 
in patients with probable and possible sumatriptan-associated chest pain, gave no 
material change of the results. 
All drugs dispensed in the period between May 1991 and January 1995 were 
studied. In table 5 differences in use of gastrointestinal drugs between patients with 
and without chest pain after sumatriptan are shown. 
TABLE 5 
Differences in use of gastrointestinal drugs during the study period beh~leell patients with and 
without chest pain after use of sUlnatriplafl* 
Drugs 
Total 
- Antacids 
- H2-antagonists 
- ProtoIl-pump 
inhibitors 
- Cisapride 
- Any of the above 
Chest pain after sumatriptan 
N (%) 
104 
11 (10.6) 
16 (15.4) 
4 (3.B) 
7 (6.7) 
26 (25.2) 
* of the total of 280 patients whose information was available 
No statistically significant differences 
Discussion 
No chest pain after sumatriptan 
N (%) 
176 
16 (9.1) 
19 (IO.B) 
10 (5.7) 
B (4.5) 
32 (IB.3) 
The primary aim of this study was not to demonstrate that sumatriptan can cause chest 
pain, since ample support for this association has been obtained from a number of case 
reports, clinical trials and postmarketing studies (3). Our primary aims were to 
identify characteristics and independent risk factors for chest pain attributed to 
sumatriptan, which may contribute to better prescribing and understanding of the 
nature of this adverse drug reaction. 
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Chest pain occurred faster after subcutaneous administration than after oral 
administration, whereas the duration of chest pain was shorter after subcutaneous 
administration. These relationships suggest a dose-response relation between 
sumatriptan and chest symptoms, since subcutaneously administered sumatriptan has a 
faster peak plasma concentration which also decreases faster (1). It is of clinical 
importance that in almost all patients (96%) chest pain after sumatriptan disappeared 
within 2 hours, so if chest pain continues for longer than 2 hours this should be 
viewed as an unusual reaction which requires special attention. It seems prudent that 
in these cases electrocardiography is performed to exclude myocardial infarction. 
The results of our study suggest a vascular mechanism of the chest complaints after 
use of sumatriptan. There also was a weak association of sumatriptan-associated chest 
pain and complaints of dyspepsia in our study. A gastrointestinal mechanism of chest 
symptoms after sumatriptan has been suggested in a recent study, in which a small 
group of volunteers had abnormal oesophageal contractions after a supratherapeutic 
dose of sumatriptan (20). However, the design and implications of this study have 
been challenged (21). Furthermore, a previously reported case-history described a 
patient with sumatriptan associated chest pain without alterations of the pressure in the 
oesophagus following a sumatriptan injection (22). The association of chest symptoms 
after sumatriptan with general complaints of dyspepsia in our study, could be 
compatible with a gastrointestinal mechanism in a proportion of the patients. 
Unfortunately, we have no detailed information on the abdominal complaints. 
Abdominal pain is not a feature of migraine in adults (23). Moderate, not statistically 
significant, differences were demonstrated in our study in use of gastrointestinal drugs 
between patients with and without chest pain after sumatriptan. Patients with chest 
pain more frequently used H,-antagonist (15.4% vs. 10.8%), but less frequently 
proton-pump inhibitors (3.8% vs. 5.7%). 
The association of sumatriptan-induced chest pain and hypertension, the presence 
of Raynaud's phenomenon, angina pectoris and a family history of myocardial 
infarction, suggest a vascular mechanism of the chest symptoms. A vascular 
mechanism of the chest symptoms, with in particular involvement of coronary arteries 
is suggested by a number of case reports concerning cardiac side effects after use of 
sumatriptan. It has been suggested that this may be mediated by endothelial 
dysfunction (24). Chest symptoms in our study were associated with hypertension. An 
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association between endothelial function and hypertension has previously been 
demonstrated (25-28). This may also explain the observation in our study that notably 
in males hypertension was a strong risk factor for sumatriptan-associated chest pain 
(29). However, other determinants of endothelial dysfunction, such as 
hypercholesterolaemia (26, 30) or smoking (31, 32), were not associated with chest 
pain attributed to use of sumatriptan in our study. Males with chest pain after 
sumatriptan had a higher cholesterol and LDL-cholesterol than males without chest 
pain after sumatriptan. Probably because the number of patients in these groups was 
small these differences were not statistically significant. 
Our study has several limitations. Not all cases experienced chest pain after each 
administration of sumatriptan. It is possible that certain variables modify the risk of 
chest pain associated with sumatriptan within a patient, e.g. smoking during use of 
sumatriptan. This could not be studied in this study since no relevant data were 
collected. A case cross-over study might offer a better approach to assess potential 
transient risk factors during use of sumatriptan in future studies (33). 
We previously demonstrated the cumulative incidence of chest pain attributed to 
sumatriptan to be approximately 8 %, which is higher than observed in the clinical 
trials. It is possible that we found a higher frequency of chest pain, because in clinical 
trials patients with hypertension were excluded (34). Hypertension is also listed among 
the contra-indications in the product information of sumatriptan. However, because 
hypertension is often not recognized sumatriptan is probably often used by 
hypertensive patients with severe migraine or cluster headache. In a previous part of 
our study (16), 22 out of the 414 males had chest pain on one or more occasions after 
administration of sumatriptan (5.3%; 95% CI 3.2 - 7.5%). Conservatively based on 
the lower boundary of the 95 % confidence interval, this would be compatible with a 
cumulative one-year incidence in hypertensive males of approximately 30 percent. 
In conclusion, we demonstrated several characteristics and determinants of 
sumatriptan associated chest pain. The chest symptoms appear to have a dose-effect 
relationship with use of sumatriptan, whereas the duration in most patients is not 
longer than 2 hours. After multivariate analysis, young age, hypertension, general 
complaints of abdominal pain, a family history of myocardial infarction and Raynaud's 
phenomenon were associated with an increased risk of chest pain attributed to 
sumatriptan. Especially in males, hypertension and a family history of myocardial 
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infarction were strong risk factors. These findings are compatible with a vascular 
mechanism of chest pain (with possibly involvement of coronary arteries) in some 
patients. 
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CHAPTER 10 
CARDIAC EXERCISE TESTING IN PATIENTS WITH 
CHEST PAIN DUE TO SUMATRIPTAN 
Submitted 
Introduction 
Sumatriptan is a relatively new drug for the treatment of acute attacks of migraine and 
cluster headache (1, 2). It is a serotonin-l (5HT -1) agonist which can be administered 
orally or subcutaneously. It has been estimated that 3-8 % of the consumers of 
sumatriptan experience chest pain after use of the drug (3-5). These chest symptoms 
have been associated with both cardiac disturbances (6-9) and abnormal oesophageal 
contractions (10). Both intravenous and subcutaneous administration of sumatriptan 
result in a significant reduction in coronary artery diameter (11, 12), an effect which 
can be reversed by administration of glyceryl trinitrate (13). 
To assess whether chest pain attributed to sumatriptan is associated with 
abnormalities on cardiac exercise testing, we performed a case-control study. 
Patients, methods and analysis 
Patients 
A cohort study on adverse reactions to sumatriptan was performed in The Netherlands 
with assistance of drug dispensing general practitioners (GPs) as described in detail 
previously (3, 5). The study protocol was approved by the Research Ethics Conmlittee 
of the University Hospital 'Dijkzigt' Rotterdam (MEC 140.112/1994/168), and written 
informed consent was obtained from all patients. 
From this cohort, cases were selected as consumers of sumatriptan who reported 
sumatriptan associated chest pain. Location of the pain or anginal sensations in 
association with intake of sumatriptan, had to be at the sternum, left thoracic wall or 
left shoulder, and had to occur within 6 hours after administration of sumatriptan. 
Cases were included if they were able and willing to perform an exercise test. They 
were asked about participation in (this part of) the study, during a home visit in a 
previous part of the study. 
A reference group was selected randomly from consumers of sumatriptan with the 
same GP as the case, who reported no chest pain after use of sumatriptan. If possible, 
controls were matched for age (within 5-year groups) and gender. 
Of the 130 potential cases who were visited at home, nine subjects were unable to 
exercise, three subjects were lost to follow-up because of a change of residence, and 
seven subjects refused to participate in an exercise test, resulting in a total of 111 
potential cases. 
For 16 cases, no control could be selected mainly because the general practitioner 
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of the case had only one patient (= case) on sumatriptan. This resulted in 95 potential 
controls. 
Methods 
Symptom-limited exercise tests were performed in hospitals in the neighbourhood of 
the subjects, with either a treadmill or bicycle ergometer, mostly using the Bruce 
protocol or a protocol with 20 Watts per minute workload increments respectively. 
Electrocardiography (ECG) and heart rate were continuously monitored, and recorded 
every three minutes. Blood pressure was measured and recorded every three minutes. 
A horizontal or downs loping ST segment depression of at least 0.1 mV extending 
at 80 msec after the J point was considered as abnormal. The exercise tests were 
evaluated by cardiologists in the hospitals. A random sample of 10% of the ECGs 
were re-evaluated by a cardiologist who had no knowledge as to whether it concerned 
a case or a control. 
Analysis 
Differences between group means were tested by Student's t test. A chi-square test 
was used to assess differences between proportions, with use of Fisher's exact test if 
there was an expected cell value of less than 5. All calculated P values are two-tailed, 
with statistical siguificance defined by a two-sided p-value less than 0.05. 
Results 
In a total of 74 cases (67%) and 55 controls (58%) symptom-li.mited exercise tests 
were performed. General characteristics of the study population are summarized in 
table 1. 
TABLE 1 
Basic characteristics of the study population 
Characteristic Cases Controls 
Number or mean (% or SE) Number or mean (% or SE) 
Number 74 55 
Age (years) 43 (1.2) 47 (1.3)# 
Females 6t (82) 46 (84) 
Resting blood pressure (mm Hg): 
Systolic 133 (2.3) 131 (2.5) 
Diastolic 83 (1.2) 82 (1.6) 
Serum cholesterol (mmolil) 5.9 (0.14) 5.8 (0.17) 
Smoking 20 (27) 15 (27) 
Family history of myocardial infarction 15 (20) 10 (18) 
SE = Standard Error; # p<O.OI 
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In cases, non-responders more frequently had a family history of myocardial infarction 
(20% and 36% respectively, p=0.05), other characteristics did not differ between 
responders and non-responders. Besides a small difference in age, there were no 
differences in basic characteristics between cases and controls. In males, cases had a 
moderately increased resting systolic blood pressure of 134 mlll Hg as against 126 mOl 
Hg in controls, a difference which was not statistically significant (p=0.21). None of 
the patients used sumatriptan during the exercise test. 
Two patients (both cases) had an abnormal resting ECG: one patient had left 
ventricular hypertrophy (L VH) and one patient had a left bundle branch block. The 
patient with LVH on resting ECG concerned a 42-year-old male with a medical 
history of chronic obstructive lung disease and hypertension. 
The results of exercise testing are shown in table 2. 
TABLE 2 
Results of exercise testing in 74 patients with suma/riptan-induced chest pain (cases) and 55 consumers of 
suma/riptan without sllch complaints (controls) 
Characteristic Cases Controls 
Number or mean (% or SE) Number or mean (% or SE) p-value 
Number 74 55 
Maximal workload (watt) 150 (4.2) 146 (6.3) 0.34 
Angina pectoris 0 0 
Maximal bloodpressure (mm Hg): 
- Systolic 180 (2.9) 183 (3.4) 0.38 
- Diastolic 87 (2.4) 86 (2.1) 0.92 
Maximal heali rate 162 (2.5) 158 (3.0) 0.32 
ST -depression 3 (4) 0 
The conclusions of the re-evaluation of the ECGs did not differ from the conclusions 
reached by the cardiologists in the different hospitals. None of the variables measured 
differed significantly between cases and controls. Three cases had ST-depression on 
ECG during exercise (mean age 51 years, I male, 2 females). During exercise, one 
patient (case) developed a quadrigeminy. In males, cases had a moderately higher 
diastolic maximal blood pressure compared to controls: 94 ll1lll Hg (SE 3.5) and 84 
mm Hg (SE 3.2) respectively (p=0.05). 
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Discussion 
In this case-control study, no differences could be demonstrated in exercise tests 
results between patients with and without sumatriptan-induced chest pain. Of the 74 
cases, 3 subjects had, however, ST-segment depression on ECG during exercise. 
Certain limitations of our study need to be mentioned. The size of the study was 
relatively small, with a higher response in cases than in controls. We do not know 
whether the non-response of 33% (cases) and 42% (controls) has influenced our 
results. However, except for a family history of myocardial infarction, none of the 
basic characteristics were different between responders and non-responders. 
Furthermore, 80% of the study population was female, and the diagnostic value of 
stress testing in women is controversial, in particular in women with low prior 
probability of coronary artery disease (14, 15). 
One question is whether sumatriptan-induced chest pain is associated with 
myocardial ischemia in a majority of the patients. It can, however, not be concluded 
from a normal exercise test that a subject had no myocardial ischemia during 
sumatriptan-induced chest pain. Previously, the case-history has been described of a 
patient with sumatriptan-associated chest pain and normal coronary angiography but 
with a positive ergonovine provocation test (16). 
It has been suggested that coronary vasospasm after sumatriptan may be caused by 
(occult) endothelial dysfunction (17). According to this mechanism, the coronary 
effects of sumatriptan may be comparable to those of serotonin itself and acetylcholine 
(18, 19). Exercise tests are not very suitable for the investigation of such endothelial 
abnormalities. Future studies with use of non-invasive methods to detect endothelial 
dysfunction in patients with and without sumatriptan-induced chest pain may give 
more insight into this mechanism (20, 21). 
In conclusion, the prevalence of abnormal exercise tests in patients with 
sumatriptan-induced chest pain is low. In future studies on sumatriptan-induced chest 
pain provocation tests with either sumatriptan or ergonovine accompanied by (non-
invasive) methods for detecting endothelial dysfunction may be used as a potentially 
more sensitive predictor of this adverse reaction. Based on the results of our study we 
do not recommend routine performance of exercise testing in patients with 
sumatriptan-induced chest pain. 
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GENERAL DISCUSSION 
GENERAL DISCUSSION 
Main findings in our studies 
In this final chapter the main findings, limitations, supporting evidence from the 
literature, clinical importance and suggestions for further studies are briefly discussed and 
summarized. Through the voluntary reporting scheme of the Netherlands Centre for 
Monitoring of Adverse Reactions to Drugs, we became aware of several cardiovascular 
adverse reactions to the new antimigrainous drug sumatriptan. Firstly, several reports of 
chest pain attributed to use of sumatriptan were received. Secondly, there was a report 
about a patient who developed an acute myocardial infarction, shortly after administration 
of sumatriptan 6 mg subcutaneously. In view of the close temporal relationship between 
use of sumatriptan and these reactions, a causal relation seemed to be probable. These 
reports gave, however, no insight into the frequency of the adverse reactions to 
sumatriptan, and their risk factors. 
We performed a pharmaco-epidemiologic study with assistance of drug-dispensing 
general practitioners (GP). Because these GPs have direct access to both data on drug 
dispensing and on disease and because of their excellent co-operation (response rate 
86%), this group of physicians appeared a very useful resource to study acute problems 
with adverse reactions to newly marketed drugs. According to the GP records, chest pain 
was noted in approximately 1 % of the consumers. According to the consumers 
themselves, approximately 8% had experienced chest pain after administration of 
sumatriptan. Furthermore, it was demonstrated that a small proportion of the consumers 
(4%) used sumatriptan very often, a pattern of use that was more frequent in males and in 
those patients with a reported poor efficacy of sumatriptan. 
Chest pain to sumatriptan occurred faster after subcutaneous administration than after 
oral administration, whereas the duration of chest pain was shorter after subcutaneous 
administration. TillS is compatible with a dose-response relationship. In almost every 
patient (96%) chest pain disappeared within 2 hours. In a multivariate analysis, young 
age, hypertension, general complaints of abdominal pain, a family history of myocardial 
infarction and Raynaud's phenomenon were associated with an increased risk of chest 
pain attributed to sumatriptan. There were differences in the strength of the risk factors 
between males and females. In paliicular in males, hypertension and a family history of 
myocardial infarction were strong predictors of sumatriptan-associated chest pain. 
Exercise testing in patients with chest pain due to use of sumatriptan hardly revealed 
any abnormalities, and is not a useful diagnostic tool for this condition. 
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Limitations of the studies 
The sample size of our study (approximately 1700 patients) was too small to observe rare 
adverse reactions, for instance those with an incidence below 1 per 1000 users. It was, 
for example, not possible to estimate the exact incidence rate of acute myocardial 
infarction due to sumatriptan. 
In our cohort study on the frequency of adverse reactions to sumatriptan, we did not 
include a reference group. For this, there were several considerations. Firstly, we were 
mainly interested in adverse reactions with a close temporal relationship with use of 
sumatriptan, and with a relatively low background incidence in the middle-aged. 
Sumatriptan is mostly used for short periods. As it is unlikely that many reference 
patients would have developed chest pain in the same short periods in which the index 
patients were exposed, a reference group was not deemed necessary to obtain a valid 
estimate of the frequency of the event. A recent postmarketing clinical trial, in which 
sumatriptan was compared to both placebo and aspirin, confirmed that chest pain occurred 
in approximately 5% of the consumers of sumatriptan but in none of the patients after 
administration of a placebo or aspirin (I). Secondly, as sumatriptan is contraindicated in 
patients with angina pectoris and variant angina, such patients might have been 
overrepresented in a reference group of patients with migraine. 
In our study on determinants of chest pain to sumatriptan, not all cases experienced 
chest pain after each administration of sumatriptan. It is possible that certain variables can 
modify the risk of chest pain associated with sumatriptan within a patient, e.g. smoking 
during use of sumatriptan. However, this could not be investigated in this study since the 
required time specific data could not be collected. 
The size of our study with exercise tests was relatively small. Moreover, if myocardial 
ischemia due to use of sumatriptan is associated with endothelial dysfunction rather than 
with coronary stenoses (2), exercise tests give only limited information. 
Supporting evidence from the literature 
Our reports on chest pain and acute myocardial infarction were soon confirmed by other 
reports in the literature (see chapter 6). Although several pre-marketing clinical studies 
did not mention chest pain as an adverse reaction to sumatriptan (3, 4), a post-marketing 
clinical trial did clearly demonstrate the occurrence of this adverse reaction (I). 
There is some pharmacological evidence for myocardial ischaemia due to sumatriptan. 
Sumatriptan constricted isolated coronary arteries of beagle dogs (5). Human isolated 
basilar artery rings constricted in response to sumatriptan (6), as did human epicardial 
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coronary artery rings from explanted hearts. Furthermore, two small studies, in which 
patients undergoing diagnostic coronary arteriography were studied, demonstrated a 
significant reduction in coronary artery diameter after both intravenous and subcutaneous 
administration of sumatriptan (7, 8). 
Our findings suggested a dose-response relation between sumatriptan and the 
occurrence of chest pain. An increasing incidence of chest symptoms with a higher dose 
of sumatriptan has been observed in one dose-finding study (9). This may also be of 
clinical importance, as a small proportion of the consumers of sumatriptan administrates 
sumatriptan very often, which was also observed in Denmark (10). 
Clinical importance of our findings 
Chest pain after use of sumatriptan seems to be a relatively common (8 %) adverse 
reaction to this dlUg. Since myocardial infarction due to sumatriptan has been reported, 
each case of chest pain after administration of sumatriptan, requires a careful evaluation, 
with respect to factors such as duration of chest pain, severity of the reaction and the 
presence of recognized cardiovascular risk factors. If chest pain after use of sumatriptan 
continues for longer than 2 hours, this consists of an unusual reaction which requires 
special attention. Several risk factors for chest pain to sumatriptan, such as young age, 
hypertension, general complaints of abdominal pain, a family history of myocardial 
infarction and Raynaud's phenomenon, warrant careful use of sumatriptan in patients with 
one 01' more of these characteristics. Particularly in males with hypertension or a family 
history of myocardial infarction, there is a high probability of chest pain after use of 
sumatriptan. 
Exercise testing is often used as a diagnostic tool in the evaluation of angina pectoris. 
It concerns, however, a relatively expensive and insensitive method. Based on the results 
of our study, we advise against routine performance of exercise testing in patients with 
sumatriptan-induced chest pain. 
According to the potential risk of over-use of sumatriptan, it is important to evaluate 
the treatment of headache attacks with sumatriptan in every patient, in particular in males 
who report a poor efficacy of sumatriptan. 
Suggestions for further studies 
A number of questions merits further research. It may be interesting whether within one 
patient transient determinants increase the risk of chest pain after use of sumatriptan. A 
case cross-over study might offer a useful approach to assess potential transient risk 
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factors during use of sumatriptan in future studies, such as smoking during use of 
sumatriptan. 
It is important to identify risk factors for serious (cardiovascular) adverse reactions to 
sumatriptan. A case-control study of patient characteristics in reports of serious cardiac 
adverse reactions to sumatriptan like myocardial infarction (cases), compared to 
characteristics in consumers of sumatriptan with mild chest pain after use of the drug 
(=controls), may give insight into risk factors for serious cardiac reactions after use of 
sumatriptan. This approach to identify risk factors for relatively rare adverse reactions has 
previously been described in the study on risk factors for the development of 
flucloxacillin associated jaundice (II). 
With regard to the mechanism of sumatriptan-induced chest pain, it may be useful to 
assess a possible association of this adverse reaction with endothelial dysfunction. In 
future studies on sumatriptan-induced chest pain, a provocation test with either 
sumatriptan or ergonovine accompanied by (non-invasive) methods for detecting 
endothelial dysfunction may be used as a potentially more sensitive predictor of this 
mechanism to explain the adverse reaction. 
n has previously been demonstrated that low-dose aspirin in-vitro reduces constriction 
of coronary arteries (12). In order to prevent myocardial ischaemia due to sumatriptan-
induced coronary vasoconstriction, the protective effect of aspirin may be investigated in 
controlled clinical studies. 
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SUMMARY 
SUMMARY 
The objective of the work presented in this thesis was to assess adverse drug reactions to 
the new antimigrainous drug sumatriptan in a postmarketing setting, with emphasis on the 
cardiovascular adverse reactions to this drug. The thesis is divided into three parts. Part I 
introduces the background of the project and postmarketing surveillance. Parts II 
summarizes case reports to the Netherlands Centre for Monitoring of Adverse Reactions 
to Drugs, in particular reports concerning cardiovascular adverse reactiollB to sumatriptan. 
In part III the exploration of the potential problem, chest pain and myocardial infarction 
to sumatriptan, is discussed. 
Chapter 1 provides a general introduction and describes the outline of the project. It is 
emphasized that at the time of the marketing of a new drug not all adverse drug reactions 
can be known, and that the pharmacological effects of the drug are only studied in a 
selected population. A brief discussion follows about the treatment of migraine, with 
reference to the difference between dmgs used against acute attacks of migraine, and 
drugs used for prophylactic use. 
Chapter 2 describes postmarketing surveillance. After an introduction on tltis subject, 
several aspects of premarketing studies are discussed. Next, a brief description follows of 
the history of adverse drug reactions. Finally, the limitations of premarketing studies and 
the methods of post marketing surveillance are described. 
In chapter 3 the Netherlands Centre for Monitoring of Adverse Reactions to Drugs is 
introduced. The centre was initiated after the thalidomide disaster in the 60s. In the past 
years, an increase in the aImual number of reports to the centre has been observed. 
Chapter 4 gives a review of reports of drug-induced chest pain or myocardial infarction 
as received by the Netherlands Centre for Monitoring of Adverse Reactions to Drugs 
between January 1975 and January 1995. These comprised 130 reports (71 %) of drug-
induced chest pain and 54 reports (29%) of dmg-induced myocardial infarction. The most 
frequently reported suspected drugs were the antimigrain drug sumatriptan (33 reports, 4 
concerning myocardial infarction), the calcium antagonist nifedipine (9 reports, 2 of 
myocardial infarction) and nicotine (9 reports, five concerning myocardial infarction, 8 
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patches, 1 chewing gnm). 
In chapter 5 the reports to the Netherlands Centre concerning adverse reactions to 
sumatriptan are discussed. Firstly, reports of chest pain attributed to use of sumatriptan 
are reviewed. Iu particular, the possibility that this concerns a symptom of myocardial 
ischaemia is discussed. Secondly, the case history is described of a 47-year-old woman 
with an acute myocardial infarction after administration of sumatriptan 6 mg 
subcutaneously for cluster headache. 
In chapter 6, the published cardiovascular adverse reactions to sumatriptan are reviewed, 
with attention to the phalmacological profile of the drug. Furthermore, the possible 
relationship between migraine per se and cardiovascular disease, the association between 
serotonin and cardiovascular disease, and the differential diagnosis of chest pain are 
discussed. It is concluded that, although severe cardiovascular adverse reactions to 
sumatriptan may be rare, every case of chest pain after administration of sumatriptan, 
requires careful evaluation. 
To study the incidence of cardiovascular adverse reactions to sumatriptan, a 
pharmacoepidemiological study was performed, which is described in chapter 7. Chest 
pain attributed to sumatriptan occurred in 1.3 % of the consumers according to the general 
practitioners, and according to the consumers themselves in 7.9%. 
In chapter 8 the pattern of use and over-use of sumatriptan is described. A small group of 
patients (4 %) used sumatriptan too often. A high intake was associated with both male 
gender and a reported poor efficacy of sumatriptan. 
Chapter 9 describes characteristics and determinants of sumatriptan-associated chest pain. 
The findings show a dose-response relation between sumatriptan and chest pain. After 
multivariate analysis, young age, hyperteruion, general complaints of abdominal pain, a 
family history of myocardial infarction and Raynaud's phenomenon were associated with 
an increased risk of chest pain attributed to sumatriptan. There were differences in the 
magnitude of the risk factors between males and females. The results may have 
consequences for both prescribing and understanding of the possible mechanism of this 
adverse reaction. 
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Finally, chapter 10 describes exercise tests which were performed in patients with chest 
pain attributed to sumatriptan and in matched controls. There were no statistically 
significant differences between cases and controls in results of exercise testing. 
Furthermore, patients with chest pain associated with use of sumatriptan have a low 
prevalence of abnormal exercise tests: of the 72 cases, 3 patients (4%) had ST-depression 
during exercise, of whom two were females. Routine performance of exercise testing in 
patients with uncomplicated sumatriptan-induced chest pain is not recommended. 
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SAMENVATTING 
SAMENVATTING 
Het doel van het onderzoek dat wordt beschreven in dit proefschrift, was het 
onderzoeken van bijwerkingen van het niellwe anti-migraine middel sllmatriptan 
(Imigran), zoals deze worden waargenomen in de dagelijkse praktijk. In het bijzonder 
de cardiovasculaire bijwerkingen werden onderzocht. Het proefschrift bestaat uit drie 
gedeelten. In deel I worden algemene achtergronden van het onderzoek en van 'post 
marketing surveillance' beschreven. In deel II wordt een samenvatting gegeven van 
meldingen aan het Bureau Bijwerkingen Geneesmiddelen, in het bijzonder met 
be trekking tot cardiovasclliaire bijwerkingen van sumatriptan. In deel III wordt een 
farmaco-epidemiologisch onderzoek beschreven, dat werd uitgevoerd naar aanleiding 
van de meldingen van pijn op de borst en hartinfarct na gebrllik van sllmatriptan. 
Hoojdslilk 1 biedt een algemene inleiding en geeft een overzicht van het proefschrift. 
Er wordt gesteld dat op het tijdstip van introdllctie op de markt van een niellw 
geneesmiddel nog niet alles over mogelijke bijwerkingen bekend is, en dat de meeste 
farmacologische effecten van het niellwe geneesmiddel aileen zijn bestlldeerd in een 
geselecteerde patienten-groep. In het hoofdstuk wordt tevens de behandeling van 
migraine besproken, waarbij een onderscheid dient te worden gemaakt tussen 
behandeling van aanvallen, en maatregelen tel' voorkoming van aanvallen. 
Hoojdsluk 2 geeft een beschrijving van 'postmarketing surveillance'; het volgen van 
een geneesmiddel na het verschijnen op de markt. In dit hoofdstuk wordt onder andere 
een samenvatting gegeven van de geschiedenis van bijwerkingen van geneesmiddelen. 
Daarnaast wordt ingegaan op de beperkingen van het onderzoek v66r registratie en 
methoden die gebruikt worden bij de postmarketing surveillance. 
In iloojdsfuk 3 wordt een beschrijving gegeven van het Bureau Bijwerkingen 
Geneesmiddelen. Dit landelijke meldingssysteem werd opgericht na de problemen rond 
thalidomide (Softenon) in de 60'er jaren. In de afgelopen jaren werd een dllidelijke 
toename van het jaarlijkse aantal meldingen waargenomen. 
Hoojdsfuk 4 geeft een overzicht van de meldingen van pijn op de borst of hartinfarct 
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door geneesmiddelen, zoals gemeld bij het Bureau Bijwerkingen Geneesmiddelen in de 
periode januari 1975 tot januari 1995. Dit betrof 130 meldingen van pijn op de borst 
en 54 meldingen van een hartinfarct in relatie tot gebruik van geneesmiddelen. 
Sumatriptan was het geneesmiddel dat het meest frequent verdacht werd (33 
meldingen), gevolgd door de calcium-antagonist nifedipine (9 meldingen) en nicotine 
(eveneens 9 meldingen. 8 betreffende de nicotine pleisters, 1 betreffende nicotine-
kauwgom). 
In hoojdstuk 5 worden cardiovasculaire bijwerkingen van sumatriptan besproken, zoals 
deze werden gemeld bij het Bureau Bijwerkingen Geneesmiddelen. Eerst worden 
meldingen van pijn op de borst na gebruik van sumatriptan besproken, waarbij wordt 
ingegaan op de mogelijkheid dat deze bijwerking wordt veroorzaakt door 
zuurstoftekort van de hartspier (myocardischemie). Daarna wordt een melding 
besproken welke de ziektegeschiedenis betreft van een 47-jarige vrouw welke na 
toediening van 6 mg sumatriptan een hartinfarct kreeg. Deze patiente had voorheen 
nooit last gehad van het hart, maar reeds twee keer eerder na gebruik van sumatriptan 
pijn op de borst gehad. 
In hoojdstuk 6 worden de in de literaruur gepubliceerde gevallen van cardiovasculaire 
bijwerkingen van sumatriptan besproken. Er wordt in dit hoofdstuk ook ingegaan op 
de farmacologische werking van sumatriptan, de mogelijke relatie tussen migraine zelf 
en cardiovasculaire ziekten, het verband russen serotonine en cardiovasculaire ziekten, 
en de differentiaal diagnose van pijn op de borst. Er wordt geconcludeerd dat 
cardiovasculaire bijwerkingen van sumatriptan waarschijnlijk zeldzaam zijn maar dat 
iedere patient met pijn op de borst na sumatriptan bijzondere aandacht verdient. 
Verder wordt geconcludeerd dat er nader onderzoek dient te geschieden naar deze 
bijwerking. 
Teneinde meer inzicht te krijgen in de incidentie van (cardiovasculaire) bijwerkingen 
van sumatriptan werd een farmaco-epidemiologisch onderzoek gestart, hetwelk wordt 
beschreven in }lOojdstuk 7. Pijn op de borst trad volgens apotheekhoudende huisartsen 
op bij 1,3% van de patienten na gebruik van sumatriptan. Volgens de gebruikers zelf, 
trad deze bijwerking op bij bijna 8 %. 
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In hooJdstuk 8 wordt het gebruik van sumatriptan in de onderzoeksgroep beschreven. 
Een kleine groep patienten (4%) gebruikte sumatriptan erg vaak. Een (te) hoog 
gebruik kwam vaker voor bij mannen, en bij patienten die weinig baat zeiden te 
hebben van sumatriptan. 
In hooJdstuk 9 worden enkele karakteristieken en determinanten van pijn op de borst 
door sumatriptan beschreven. De resultaten lijken op een dosis-respons relatie tussen 
deze bijwerkingen en sumatriptan gebruik te wijzen. Verschillende factoren bleken 
geassocieerd met pijn op de borst door sumatriptan. Met name mannen met een hoge 
bloeddruk of een familie geschiedenis van een hartinfarct hadden een sterk verhoogd 
risico op pijn op de borst na gebruik van sumatriptan. Bij vrouwen was het fenomeen 
van Raynaud geassocieerd met het optreden van pijn op de borst na sumatriptan. 
In hoojdstuk 10 worden de resllltaten van inspanningsonderzoek beschreven bij 
patienten met en zonder pijn op de borst na gebruik van sumatriptan. Er waren vrijwel 
geen al\vijkende inspanningsonderzoeken, en de conclllsie is dan ook dat een 
inspanningsonderzoek bij patienten met pijn op de borst na gebruik van sllmatriptan, 
weinig aanvullende informatie verschaft. 
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EPILOOG 
EPILOOG 
Op de laatste bladzijden van dit proefschrift wil ik graag diegenen bedanken die in 
welke vOrln dan ook hebben bijgedragen aan de voltooiing van 'het boekje'. 
In de eerste plaats ook hier nogmaals een woord van dank aan de vele 
apotheekhoudeude huismisen en patienten die belangeloos hebben meegewerkt aan de 
totstandkoming van dit proefschrift. Zonder hun hull' en medewerking was het niet 
mogelijk geweest via de door ons beschreven methoden meer inzicht te krijgen in de 
bijwerkillgen van stlmatriptan. 
J. Verhoeff, psychiater, HoofdinspecteUl' voar de Gezondheidszorg en drs. P.H. Vree, 
apotheker, HoofdinspecteUl' voor Farmacie en Medische Technologie, maakten het 
mogelijk om het onderzoek uit Ie Voeren. Jitze en Piet, hartelijk dank voor de 
samenwerking en de wijze waarop jullie de geneesmiddelenbewaking behartigen. 
Zonder de enthousiaste steUll van dr B.H.Ch. Stricker was het in dit proefsclu'ift 
beschreven onderzoek nooit van de grond gekomen. Bruno, we hebben in de afgelopen 
jaren nauw samengewerkt, niet aileen mel betrekking lot hel in dit proefschrift 
beschreven onderzoek. We hebben veel samen gedeeld, van de 'Rotterdamse werk-inzet' 
tot de achterkant van onze pennen. Hatielijk dank voor al je inzet, hopelijk kan je de 
komende tijd wal meer vakantie-dagen opmaken. 
Een speciaal woord van dank, uiteraard, Yom mijn promotor, professor dr D.E. 
Grobbee. Beste Rick, vooral door jouw voorlYarende wijze van begeleiden, werden de 
verschillende artikelen over bijwerkingen van sumatriptan omgezet in een proefschrift. 
Professor J.H.P. Wilson dank ik voor het vertrouwen dat hij ons schonk om vanuit 
'zijn' afdeling dit onderzoek te doen, alsmede vaar zijn toestenuning am een promotor 
te zoeken wiens vakgebied dichter bij het onderzoek lag. 
Professor dr H.A. Valkenburg stond samen met Bruno en mijzelf aan de wieg van het 
'sumatriptan-onderzoek'. Hans, ik ben trots en dankbaar dat jij, de grondlegger van de 
moderne Nederlandse epidemiologie, in deze promotie-commissie wilt zitting nemen. 1k 
hoop dat je nog vele jaren je geluid in de epidemiologie zult laten horen. 
Professor dr P.R. Saxena, dr H.G.M. LeuIkens en professor dr M.L. Simoons dank ik 
voar hun bereidheid zitting te nemen in de promotie-collunissie. Professor df Simoons, 
dr PJ. de Feyler en dr C. di Mario dank ik voor hun inzet de mogelijkheden te 
onderzoeken eell invasieve studie te doen naar de cardiale effecten van sumatriptan. 
Aile collega's Vatl de Inspectie voor de Gezondheidszorg, en met name degenen van 
Farmacie en Medische Teclmologie, zowe! 01' de hoofdinspectie als in de regio, hatielijk 
dank voor de samenwerking. De ondersteuning door het secretariaat van het Bureau 
Bijwerkingen Geneesmiddelen was ononlbeerlijk, en ik wil dan ook met name de dames 
Ingrid van Doorn, Gitta Lichtendonk, Ria Runnenberg en Karin IJzendoorn hartelijk 
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bedanken voor de samenwerking, en met name vom het doorverbinden van telefoontjes 
tijdens het uitvoeren van statistische analyses. 
Ook het person eel van het 'lab Interne II' wil ik bedanken, voor het opnemen in hun 
midden van 'onderzoek naar bijwerkingen'. Ik heb nooit de indruk gehad dat jullie 
vonden dat ik te vaak op het lab verbleef! Speciaal voor jullie, die zich misschien vaak 
afvroegen wat die 'mensen van Bruno' nOll precies uitvoerden, dit boekje. Wim, Felix, 
Jan, 'Jantje', Trinet, Annie, Gardi, Marian, Rita, Darcos, Ellen, Miljam, Christien, 
Moniek, Pieter, Erik, Sonja, Anne Marie en aIle anderen die er (soms tijdelijk) gewerkt 
hebben: hartelijk dank voor aIle gezelligheid! De heren J.D. Mulder en R. Alibaks van 
het beheer Interne Geneeskunde ben ik zeer erkentelijk voor het ter zijde staan bij de 
financi"le zaken. Hans, jij nog een keer met name bedankt voor het beantwoorden van 
vragen die varieerden van 'hoeveel budget er nog was' tot vragen rond de opleiding 
inwendige geneeskunde. Ook Ineke Streefland wi! ik bedanken, omdat ze meer is dan 
een secretaresse. 
Dick Kruijssen, Bert Hofman en Arno Hoes wi! ik bedanken omdat ik dankzij hen op 
de afdeling Epidemiologic & Biostatistiek ben tertcht gekomen. Ik hoop in de toekomst 
nog eens met jullie samen te mogen werken! 
Ing. A.M. de Bruyn en 'zijn laboratorium' wi! ik bedanken voor het bepalen van het 
cholesterol. Drs. Taco van Witsen, apotheker, wi! ik danken voor zijn hulp bij de 
aanvang van het onderzoek, dr R.M.C. Herings, apotheker, voor het onderzoeken van de 
mogelijkheden een utHisatie-studie te doen, dr J.A.C. Hoorntje voor het beoordelen van 
de fietsproeven, de adviesconlluissie bijwerkingen geneesmiddelen (onder 
voorziUerschap van dhl'. W. Rosinga, arts) voor het maandelijks beoordelen van de 
meldingen, het College ter Beoordeling van Geneesmiddelen (en met name dhl'. A.P. 
Meiners, internist) voor de samenwerking, de heren Wim Vlaardingerbroek en Hans 
Westra voor de literatuur-uitdraaien, en dhl'. Henk Batens voor het vele kopieer-werk. 
De be ide paranimfen, Melanie van der Klauw en Remco Ottervanger wi! ik reeds bij 
voorbaat dmlken voor hun steun bij de verdediging van dit proefschrift. Melanie, birmen 
een (halfl) jaar sta jij er voor, alvas! succes! 
Mijn grootouders, waarvan mijn grootvader ten tijde van het promotie-onderzoek 
helaas overleed, wi! ik bedmlken voor hun niet aflatende vertrouwen en voor het feit dat 
zij mij de vrijheid gaven te studeren. 
Als laatsten in de rij van bedankte personen, maar voor mij de belangrijksten: ArmeUe 
en Wendy. Wendy, de berichten van acceptatie van artikelen waren niets vergeleken bij 
jouw eerste stappen of woorden! Annette, je hebt de afgelopen jaren niet aIleen mijn 
aanwezigheid maar vooral ook mijn afwezigheid moeten dulden. Hopelijk ziet de 
toekomst er wat dit laatste betreft wat betel' uit. 
169 

CURRICULUM VITAE 
CURRICULUM VITAE 
De schrijver van dit proefschrift werd geboren op 29 maart 1965 te Rotterdam. In mei 
1983 behaalde hij het diploma ongedeeld VWO te Rotterdam, waarna hij (na uitloten 
voor de studie geneeskunde) een jaar werkzaam was als assistent-accountant bij Moret 
& Limperg, Registeraccountants Rotterdam. Gedurende dit jaar volgde hij 1 dag per 
week de accountants-opleiding (via NIVRA). In september 1984 begon hij de studie 
geneeskunde aan de Erasmus Universiteit Rotterdam. Van 1986 tot 1988 werkte hij 
part-time voor de Stichting Trombosedienst en Artsenlaboratorium Rotterdam. 
Daarnaast deed hij van 1986 tot 1991 in het Zuiderziekenhuis te Rotterdam onderzoek 
naar prognostische factoren na een hartinfarct, in samenwerking met de afdeling 
Epidemiologie & Biostatistiek van de Erasmus Universiteit. In 1988 behaalde hij zijn 
doctoraal-examen, en in april 1991 het arts-examen. 
Van 1 mei 1991 tot 1 mei 1992 was hij als assistent-geneeskundige werkzaam op de 
afdeling cardiologie van ziekenhuis "De Weezenlanden" te Zwolle. In mei 1992 werd 
met het in dit proefschrift beschreven promotie-onderzoek begomlen, en werd hij 
aangesteld bij de 'farmaco-epidemiologie unit' van het instituut Interne Geneeskunde II 
van het Academisch Ziekenhuis Dijkzigt te Rotterdam. Tevens had hij vanaf die datum 
een part-time aanstelling (50%) als inspecteur voor de volksgezondheid bij de 
Hoofdinspectie voor de Geneesmiddelen (vanaf 1 januari 1995 de Inspectie voor de 
Gezondheidszorg) van het Staatstoezicht op de Volksgezondheid. Gedurende deze 
periode werden diverse cursussen epidemiologie gevolgd, onder meer in Boston, 
U.S.A. 
Vanaf 1 maart 1996 voIgt hij, in het kader van de opleiding tot cardioloog (opleider 
dr J.C.A. Hoorntje), de vooropleiding Inwendige Geneeskunde in het Academisch 
Ziekenhuis Dijkzigt te Rotterdam (opleider prof. J.H.P. Wilson). 
Naast bovengenoemde activiteiten is hij een enthousiast beoefenaar van karate. 
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